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Abstract
Helicobacter pylori colonizes 50% of the world’s population, whereby glycoproteins and
Lewis Y-containing lipopolysaccharides contribute to its pathogenesis. We investigated
whether the HopE porin is glycosylated, if the glycan is Lewis Y, and if this is mediated by
the putative oligosaccharide transferase HP0946 or the O-antigen ligase WaaL. Western
blotting was performed on outer membranes with anti-HopE antibodies, anti-Lewis Y
antibodies and fucose-binding BambL lectin to ascertain HopE glycosylation. We discovered
that HopE is likely glycosylated by a non-Lewis Y fucose-containing glycan and neither
HP0946 nor WaaL are the transferase. Additionally, we investigated HopE’s role in
antibiotic susceptibility via Etest strips and disk diffusion method. By comparing sets of
mutants for HopE, HP0946, and WaaL, we found that HopE does not affect antibiotic
sensitivity, while eliminating HP0946 increases antibiotic sensitivity. Overall, this study
presents HopE as a novel fucosylated glycoprotein and introduces a possible role for HP0946
in antibiotic resistance.

Keywords
Helicobacter pylori, protein glycosylation, lipopolysaccharide, glycoproteins, O- antigen,
antibiotic resistance.
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1

Introduction
An introduction to Helicobacter pylori
Helicobacter pylori is a Gram-negative, microaerophilic bacterium with a spiral

shape and several polar sheathed flagella1. Currently, it is well known that H. pylori can
survive the harsh environment of the human stomach and can cause gastritis, peptic ulcer
disease2 and gastric adenocarcinoma1. However, at the time of its discovery, the evidence
that H. pylori could successfully colonize the stomach was controversial to the longstanding belief that stress and lifestyle were the major factors in the manifestation of
peptic ulcer disease3.
H. pylori was first isolated in 1982 by two Australian researchers, Barry Marshall
and Robin Warren. Through drinking a culture of H. pylori, Dr. Marshall was able to
demonstrate the association of H. pylori infection with gastritis and peptic ulcer disease
when he developed gastritis after drinking the concoction4. Dr. Marshall’s experiment
was revolutionary as it followed Koch’s postulates for the development of H. pyloriassociated gastritis and proved that the stomach was not a sterile environment, incapable
of bacterial colonization4. As a result of this significant finding and the subsequent
association with gastric cancer, Dr. Marshall and Dr. Warren were awarded the Nobel
Prize in Physiology and Medicine in 2005 for their discovery of H. pylori’s involvement
in chronic gastrointestinal disease.

1.1.1 Clinical manifestation of H. pylori
Thirty-six years later, it is now recognized that H. pylori globally colonizes more
than half of the world’s population5. Although present throughout the world, there is a
large geographic variation in H. pylori’s prevalence based on socioeconomic factors and
levels of hygiene6. The countries with the highest prevalence are Nigeria (87.7%),
Portugal (86.4%), and Estonia (82.5%) whereas the countries with the lowest prevalence
are Switzerland (18.9%), Denmark (22.1%), and New Zealand (24.0%). While the United
States has a low prevalence of H. pylori (35.6%), its indigenous populations have a high
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prevalence (74.8%)6. According to the Canadian Digestive Health Foundation, 10 million
(27.5%) Canadians are infected with H. pylori, with roughly 75% of the First Nation
communities infected.
Helicobacter pylori is the only microorganism that can cause gastric
adenocarcinoma, and it is the first pathogen to be classified as a type 1 human carcinogen
by the World Health Organization (WHO)5,7. Although only 1-3% of infected individuals
develop gastric cancer8, this represents staggering numbers of affected individuals since
H. pylori colonizes a large portion of the world’s population. This contributes to gastric
cancer being the 5th cancer worldwide for prevalence9.
In order to treat H. pylori infections, suggested regimens include triple therapy or
quadruple therapy10. Triple therapies involve the use of two antibiotics in combination
with a proton pump inhibitor. However, due to the rise in antibiotic resistance, quadruple
therapies are increasingly being prescribed. These therapies use a proton pump inhibitor,
two antibiotics, a bismuth product and/or another antibiotic11. Proton pump inhibitors are
used to suppress acid production and, in conjunction with the antibiotics, can help
alleviate ulcer-related symptoms11. To date, antibiotic resistance and lack of patient
tolerance has resulted in an increasing antibiotic treatment failure rate12. In fact, in 2017
the WHO published its first ever list of antibiotic-resistant “priority pathogens”, a list of
bacteria that pose the greatest threat to human health13. This list was created to guide and
promote the research and development of new antibiotics for these priority pathogens. On
the list, Helicobacter pylori was categorized as a “Priority 2: HIGH”, for its increasing
drug resistance to clarithromycin, which is used in first line therapies for the treatment of
H. pylori infections. Thus, it is mandatory to find novel avenues of treatment for
individuals suffering from diseases caused by chronic H. pylori infections.

4

The lipopolysaccharide (LPS)
The LPS layer is a key component of the outer membrane of H. pylori. The
structure of H. pylori’s LPS is similar to the LPS of other Gram-negative bacteria and is
composed of three domains: the hydrophobic lipid A domain embedded in the outer
membrane, the core oligosaccharide, and the variable O-antigen polysaccharide14 (Figure
1). This negatively charged structure plays a major role in providing a physical barrier
against host defenses, detergents and antibiotics15.
Each domain of the LPS has a unique function. Lipid A serves as the membrane
anchoring component and is usually an endotoxin responsible for certain pathologies
during infections. Specifically, toll-like receptor 4 (TLR4), a receptor protein on animal
cells, is activated by lipid A, inducing the release of proinflammatory cytokines via signal
transduction and triggering the innate immune response16. If the immune response is
strong enough, this activation can result in sepsis, leading to organ failure and death16.
However, H. pylori has modified lipid A (one step of the pathway being the removal of
the Kdo sugar via Kdo hydrolase, with the final step involving the removal of the 3’-Olinked acyl chain resulting in a tetra-acylated lipid A from a hexa-acylated lipid A17,18) in
order to minimize immune system activation, allowing for immune evasion and
facilitating chronic infection17. The core oligosaccharide connects lipid A to the Oantigen, and the O-antigen contributes to the antigenicity of the LPS molecule19. The LPS
of H. pylori helps propagate this pathogen in two ways: creating Lewis antigens to
facilitate host mimicry (see details below, section 1.2.2) and immune evasion20, and
resistance to host cationic antimicrobial peptides (CAMPs) via the lipid A-core21.
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Figure 1. Proposed LPS structure of H. pylori reference strain 26695.
The three domains of the LPS are: the lipid A, the core oligosaccharide (divided into
inner and outer core), and the O-antigen22.

1.2.1 LPS biosynthesis
Characterizing the LPS biosynthesis pathway of H. pylori has not been an easy
task. This is partially due to the genes involved in LPS biosynthesis being spread
throughout the genome rather than organized into an operon like in most Gram-negative
bacteria. However, in recent years there has been significant progress in our
understanding of H. pylori’s LPS synthesis process.
There are three possible pathways for the biosynthesis of the O-antigen: the Wzydependent pathway, the ABC-transporter-dependent pathway, and the synthase dependent
pathway22, the first two being the most common. All three pathways commence in a
similar fashion; WecA transfers a N-acetylglucosamine (GlcNAc) phosphate from UDP-
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GlcNAc to undecaprenyl pyrophosphate (Und-PP)23. Then the three pathways differ in
terms of O-antigen creation and translocation22. It was expected that H. pylori uses a
Wzy-dependent pathway, in which short O-antigen units are assembled and translocated
to the periplasm via Wzx flippase, where they are polymerized by Wzy into the correct
length with the help of Wzz and then ligated to the lipid A-core23. However, no homologs
for wzx or coding sequences for the Wzy and Wzz enzymes existed in H. pylori23.
Surprisingly, H. pylori O-antigen synthesis follows a unique Wzk-dependent
pathway (Figure 2), with Wzk being a translocase that enables the production of variablelength O-antigens23. In this pathway, the Und-PP-GlcNAc resulting from WecA activity
acts as an acceptor for the assembly of the O-antigen. Next, glycosyltransferases add
alternating Gal and GlcNAc residues to create the O-antigen backbone23. Then, α1,3fucosyltransferases FutA and FutB attach fucose molecules to select GlcNAc residues,
creating Lewis X. The α1,2- fucosyltransferase FutC transfers fucose to the terminal Gal
to generate Lewis Y24 (Figure 3). Notably, H. pylori displays a large diversity of Lewis X
and Y expression on the LPS, with FutA and B acting as enzymatic rulers for
fucosylation, only adding fucose to O-antigen polymers of specific lengths, based on the
number of heptad repeats in the amino acid sequence of FutA and B24. This variability of
the Lewis antigen expression pattern is likely in response to environmental changes, such
as changes in pH25 and host blood group antigens, which would promote adaptation of
certain individual isolates to their host environment and facilitate further immune
evasion24. Once assembled, the O-antigen is translocated to the periplasm by the flippase
Wzk and ligated to the lipid A-core by O-antigen ligase WaaL23. Interestingly, the Wzk
enzyme was found to be dissimilar to other translocases but homologous to
Campylobacter jejuni (CJ) PglK, a flippase of Und-PP-heptasaccharide used for protein
N-glycosylation23,26.
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Figure 2. Novel LPS biosynthesis pathway in H. pylori.
LPS synthesis starts when WecA transfers GlcNAc (N-acetyl glucosamine) to UndP
(undecaprenyl pyrophosphate). Next, glycosyltransferases (GalT and GlcNAcT)
alternately add Gal and GlcNAc residues, producing the linear O chain backbone. Then,
fucosyltransferases (FucTs) attach fucose residues on selected locations of the O-antigen
backbone, generating Lewis antigens. The flippase Wzk transfers this O-antigen to the
periplasm, where it is attached onto the lipid A-core via the O-antigen ligase WaaL. Once
the LPS molecule is assembled, it can be transported to the outer membrane by Lpt
(lipopolysaccharide transport) proteins (a transenvelope complex)23.
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Figure 3. Enhanced view of a Lewis Y LPS structure.
The Lewis Y O-antigen is formed by the attachment of fucose to the terminal Gal in an α1,2 linkage and to the preceding GlcNAc in an α-1,3 linkage. The R refers to the rest of
the molecule. Adapted from Hug et al.23 and expanded upon (Creuzenet lab).

1.2.2 Lewis O-antigens and host mimicry
As introduced above, the LPS of H. pylori is unique in that it expresses Lewis
Blood Group antigens and presents them on the O-antigen domain20. These are
carbohydrates that are commonly associated with host monocytes, macrophages,
granulocytes and gastric epithelial cells20. Predominantly, 80-90% of H. pylori strains
produce type 2 blood group antigens Lewis X and Lewis Y on the LPS27,28. The pathogen
also expresses type 1 blood group antigens Lewis A, Lewis B, Lewis C and H-antigens at
a lower frequency29. Molecular mimicry by these antigens allows for H. pylori’s
protection against recognition as a foreign invader and facilitates successful immune
evasion20. However, upon recognition of the pathogen over time, this mimicry also
causes an autoimmune response, leading to inflammation and tissue damage20.
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1.2.3 Phase variation
H. pylori is known to be very genetically diverse30. One method of increasing
diversity is phase variation (or antigenic variation), in which surface epitopes, like those
presented on the LPS, are reversibly switched on-and-off 31. A proposed mechanism for
phase variation is strand slippage during DNA replication in regions with homopolymeric
tracts or oligonucleotide repeats31. The resulting products of phase variation create a
microorganism that is more versatile and better able to cope in varying environmental
conditions31. Switching on certain genes may allow this microorganism to adhere better
to mucosal cells or decrease antigenicity and recognition by antibodies; switching off
certain other genes may result in the reverse effect31. It has been determined that
fucosyltransferases involved in Lewis X and Y antigen assembly undergo phase
variation31, due to their homopolymeric tract which is denoted as the frame shifting
region in Figure 4.
In fact, there are a total of 27 predicted phase variable genes in H. pylori, several
of them from the Hop outer membrane family. This includes porins HopC and HopD,
HopM, and adhesin HopZ. In general, phase variation could explain the differences in
isolates found within different human hosts.
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Figure 4. H. pylori fucosyltransferases responsible for Lewis X and Y antigens.
A) Lewis antigen structures and the pathway with enzymes involved in their synthesis. B)
FutA and B (α1,3- fucosyltransferases), indicating frame shifting in the 5’ polyC tract,
with the 7 amino acid heptad region determining the size of the O-antigen polymers that
become fucosylated. C) FutC (α1,2- fucosyltransferase), frame shifting in the middle of
the gene resulting in variable expression of Lewis glycosylation24.

11

Helicobacter pylori’s outer membrane proteins (OMPs)
Through bioinformatics analysis of H. pylori J99 and 26695, five paralogous gene
families of outer membrane proteins (OMPs) were identified, with a total of ~64
members32. The largest family is comprised of 21 Hop (H. pylori OMP) proteins and 12
Hor (Hop related) proteins. Members of the Hop family are grouped together due to their
shared or identical amino acid sequences at the N- and C- termini32. Family 2 contains 8
Hof (for Helicobacter OMP family) proteins, characterized by their similar molecular
masses and hydrophobic C-terminal sequence motif present in most OMPs, and family 3
has 4 Hom (for Helicobacter outer membrane) proteins with conserved N- and C-termini
and the C-terminal hydrophobic motif32. The last two families are characterized due to
their homology to iron-regulated OMPs found in other bacteria, labeled FecA-like
(similar to Escherichia coli’s ferric citrate receptor) and FecB-like (similarity to
Neisseria spp.’s major iron-regulated OMP). Family 4 is comprised of iron-regulated
OMPs (6 members) and family 5 includes efflux pump OMPs (3 members). The
remaining OMPs are not members of any families (~10 members).
Five Hop members (HopA-E) from strain 26695 are characterized as porins33,
with some Hop proteins also functioning as adhesins (such as BabA and BabB)34.
Specifically, the porin HopE (31 kDa), that is the focus of this thesis, is the smallest of
these proteins and can form trimers (90 kDa)33. Like other porins, HopE is predicted to be
a β- barrel structure, containing 16 strands with alternating hydrophobic and hydrophilic
residues35. Forming atypically large water-filled channels for a porin, HopE has no
specific binding sites and no preference for anions or cations, implying that it is a major
nonspecific porin of H. pylori due to its lack of substrate specificity to ions33.
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H. pylori’s inner membrane proteins
Unlike outer membrane proteins, inner membrane proteins have not currently been
characterized and quantified to the same extent in H. pylori. However, this section will
discuss some notable inner membrane proteins.
Several of the proteins involved in LPS biosynthesis are localized within the inner
membrane, such as the aforementioned WecA, the fucosyltransferases FutA and C, the
O-antigen flippase Wzk, and the O-antigen ligase WaaL. Another essential inner
membrane protein is UreI, part of the urease gene cluster of seven open reading frames
ureABIEFGH, and survival of H. pylori in the acidic gastric environment is contingent on
the expression of this inner membrane urea channel36. This channel conveys the gastric
urea to the cytoplasmic urease, where it is hydrolyzed into carbon dioxide and ammonia,
buffering the periplasm to a pH of 6.137.
Additionally, several putative paralogous inner membrane efflux pumps have also
been identified: HefC, HefF and HefI. It is suggested that the efflux pump HefC may play
a critical role in pumping out bile salts that it encounters in vivo, specifically in the
duodenum, to prevent the antimicrobial effects of the substance38. Currently, the
functions of HefF and HefI are unknown.
Lastly, HP0946 is a protein of interest in this thesis. Through in silico analysis
conducted in the lab, it is a predicted inner membrane protein with 13-14 transmembrane
domains (depending on the software) and is currently annotated as a sodium-proton
antiporter. Additionally, our lab discovered that HP0946 shares some similarity to a wellknown oligosaccharide transferase in C. jejuni, PglB, an enzyme that is involved in
protein glycosylation. HP0946 is also predicted to have 2-3 large periplasmic loops that
may interact with substrates (which can be either proteins or glycans). As such, it would
be of interest to further investigate the function of HP0946 and determine if there is any
connection to the LPS biosynthesis pathway, potentially by interacting with the Lewis
substrate and leading to glycosylation of protein(s) with this substrate.
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Protein glycosylation
Protein glycosylation is characterized as the modification of proteins through
covalent attachment of carbohydrates39. Initially, it was thought that protein glycosylation
existed only in eukaryotes, however it is now well established that protein glycosylation
occurs in prokaryotes and archaea as well. These modifications are critical for a wide
range of biological processes, such as controlling protein folding and protein stability40,
regulating intracellular trafficking, modulating enzyme and hormone activities,
participation in cell-cell interactions, and acting as cell surface receptors41.
There are two main types of protein glycosylation: N-linked and O-linked. Nglycosylation occurs via linkage of a glycan (such as GlcNAc or other) to the nitrogen in
the amido group of asparagine, whereas O-glycosylation occurs when a glycan (i.e. Nacetylgalactosamine, GalNAc or other) is attached to the oxygen in the hydroxyl group in
either serine or threonine42.
The sites at which glycosylation takes place depends on the specific sequence of
amino acids adjacent to either asparagine (Asn), serine (Ser) or threonine (Thr)42. The
consensus sequence for N-glycosylation is either Asn-X-Thr/Ser (with X being any
amino acid except proline)42. This is a well conserved sequence in eukaryotes, however
prokaryotes likely have an extension of this glycosylation sequence. Bacteria such as
Campylobacter jejuni require an extended glycosylation sequence, which is as follows:
Asp/Glu-Y-Asn-X-Ser/Thr (where X and Y are not proline)43. No widespread consensus
sequence has been determined for O-glycosylation42, however one lab was able to
determine the conserved sequence in intestinal Bacteroides species, Bacteroides fragilis,
as being Asp-Ser/Thr-Ala/Ile/Val/Met/Thr (the last amino acid must contain either one or
more methyl groups)44. To date, only Campylobacter jejuni has been found to carry both
N- and O-protein glycosylation pathways45.
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1.5.1 Protein glycosylation in eukaryotes
First discovered in eukaryotes, it is now predicted that more than two-thirds of
eukaryotic proteins undergo protein glycosylation46. Regardless of the eukaryote, the
biosynthetic machinery responsible for this modification follows a similar progression.
The eukaryotic N-glycosylation pathway starts with the assembly of the glycan in
the cytoplasm of the endoplasmic reticulum (ER) and is mediated by the membraneembedded dolichol pyrophosphate lipid carrier. The glycan is extended through the
addition of sugar molecules by embedded glycosyltransferases in a step-wise manner to
form the precursor oligosaccharide. Next, the glycan is translocated across the membrane
to the ER lumen by a currently unknown flippase protein, where the oligosaccharide
decoration is resumed by more glycosyltransferases on the lumen side and results in the
production of a conserved tetradecasaccharide (Glc3Man9GlcNAc2) core oligosaccharide.
This final oligosaccharide is then transferred en bloc to the target protein by an Noligosaccharide transferase (N-OST)47.
Comparatively, the process of eukaryotic O-glycosylation is much more variable;
currently, no dedicated O-glycosylation pathway has been identified. Although most Oglycosylation occurs in the Golgi apparatus, some O-glycosylation has been found to be
initiated in the ER. O-glycosylation begins with the addition of monosaccharide
(commonly N-acetyl-galactosamine, GalNAc) to the protein by a glycosyltransferase,
followed by sequential addition of more sugars (such as fucose, mannose, and glucose) to
form the final glycan48. Regardless of the discrepancies, both forms of eukaryotic
glycosylation contribute to the wide range of protein diversity.
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1.5.2 Protein glycosylation in prokaryotes
Since the discovery of surface layer (S-layer) glycoproteins in a Gram-negative
halophile, Halobacterium salinarium in the 1970s49, it has been well established that
prokaryotes also go through this modification, such as C. jejuni50 and H. pylori51. In fact,
the first N-linked protein glycosylation was discovered in C. jejuni52.
More than 60 N-glycoproteins have been identified in C. jejuni53. As the model
system for bacterial N-glycosylation, glycosylation initiates when a heptasaccharide is
assembled (one sugar at a time) to an undecaprenyl pyrophosphate on the cytoplasmic
side of the inner membrane. The assembled lipid-linked oligosaccharide is then flipped
across the inner membrane to the periplasm by an ATP-dependent flippase, PglK54,
similar to eukaryotic N-glycosylation. Then, an oligosaccharide transferase (OST),
PglB55, transfers the glycan to an asparagine residue on the acceptor protein. Mutations
within this pathway in C. jejuni have been shown to reduce chicken colonization56,
adherence ability, and diminish the ability to invade intestinal epithelial cells in vitro57.
Similar to N-glycosylation, O-glycosylation has been described in several bacteria
and archaea. O-glycosylation is well known to occur on bacterial surface appendages,
such as flagella and pili. Focusing on C. jejuni again, O-linked glycan modification of the
flagella is necessary for flagellum assembly, and can affect auto-agglutination, biofilm
formation and colonization of the gastrointestinal tract58. The O-linked glycans on the
flagellar proteins can constitute up to 10% of the protein mass50. Predominantly, the Oglycans attached to the flagellum are pseudaminic acid (PA) or legionomic acid
derivatives59,60.
Unlike the en bloc transfer of glycans in N-glycosylation pathways, flagellin Oglycosylation mainly occurs in a sequential pattern. In this case, glycosyltransferases
sequentially transfer monosaccharides to the target protein. Once completed, the
glycosylated flagellin monomers are secreted to the tip of the growing flagellin unit. This
form of O-glycosylation is OST-independent and is generally used to glycosylate
flagellins and non-pilus adhesins such as autotransporters61.
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Similar to the N-glycosylation pathway described in C. jejuni, OST-dependent Oglycosylation is used to glycosylate the type IV pilus of Neisseria gonorrhoeae and
Neisseria meningitidis. This pathway is initiated when the glycosyltransferase attaches a
monosaccharide to the undecaprenolphosphate (Und-P) lipid carrier located on the inner
side of the plasma membrane. Then, glycosyltransferases attach more monosaccharides to
this precursor. Once completed, the Und-P linked glycan is flipped to the periplasm and
an OST transfers this glycan to the target protein62. In addition to being similar to the Nglycosylation pathway, this general O-glycosylation also has similarities to the Wzydependent pathway involved in the production of LPS O-antigen synthesis23. Overall, Oglycosylation is widespread and not the rare event it was previously perceived to be.
However, there are still many enzymes in this pathway that have not been identified and
characterized.

1.5.2.1

Outer membrane protein glycosylation in prokaryotes

Currently, two bacterial porins have been identified as glycoproteins. Previous
research regarding a porin in Campylobacter jejuni, major outer membrane protein
(MOMP), showed that the MOMP is O-glycosylated with a glycan moiety containing one
galactose and three GalNAc residues at T268, which is in a surface exposed loop, with
this glycosylation resulting in a conformational change of MOMP63. The glycosylation of
this porin either directly or indirectly promoted cell-to-cell binding, biofilm formation,
adhesion to Caco-2 cells, and was necessary for C. jejuni’s optimal colonization of
chickens63.
The second porin, OprD of Pseudomonas aeruginosa, is a β-barrel shaped
channel-forming porin which uptakes basic amino acids, peptides and β-lactam
antibiotics. It is highly sialylated, resulting in lower penetration of β-lactam antibiotics
through this porin, indicating this may be a novel mechanism of drug resistance64. Thus,
it is possible that glycosylation of HopE may also contribute to antibiotic resistance.
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Helicobacter pylori and protein glycosylation
To date, characterizing novel protein glycosylation pathways in H. pylori and its
role on protein function has been elusive. Currently, it is known that flagellins FlaA and
FlaB that comprise of the flagellar filaments are O-glycosylated with pseudaminic acid,
which is essential for the production of the flagellum and virulence of the pathogen51.
Interestingly, mounting evidence from three individual labs suggests a connection
between flagellin glycosylation and LPS O-antigen biosynthesis in Aeromonas caviae65,
Helicobacter pylori66, and Pseudomonas aeruginosa67. Specifically, in H. pylori, the
FlaA1 enzyme is involved in the pseudaminic acid synthesis pathway for the
glycosylation of flagella51,68. This enzyme was implicated in functionally linking the
control of LPS biosynthesis and flagellum production, with protein glycosylation being
the underlying mechanism for this interconnection66. Further evidence for a link in the
two machineries is identified by the aforementioned flippase Wzk, that is homologous to
Campylobacter jejuni’s PglK enzyme that is involved in N-glycosylation26. The last piece
of evidence stems from our unpublished lab data, in which a connection was discovered
between two proteins of interest in this thesis: the O-antigen ligase WaaL, HP0946 (a
putative Lewis Y oligosaccharide transferase) and FlaA1 via RT-qPCR. HP0946
transcription expression levels were upregulated in mutants that tend to increase Lewis Y
availability: 7-fold in a waaL mutant that is unable to attach O-units for LPS assembly
and 10-fold in a flaA1 mutant that cannot utilize Und-PP-GlcNAc, a component of Lewis
antigen synthesis66.
Previously, the Creuzenet lab determined that the pseudaminic acid pathway is
not limited to H. pylori’s flagellin production, but also targets proteins involved with
virulence factor production, such as LPS and urease45. The data also identified several
non-flagellar glycoproteins using glyco-specific stains, digoxigenin-3-O-succinly-εaminocaproic acid hydrazide (DIG) labelling and mass spectrometry (MS)45. This idea
that non-flagellar proteins are glycosylated in H. pylori had also been proposed
concurrently by another lab based on global metabolic profiling, but in that study the
glycoprotein (GP) candidates had not been isolated or characterized69. In the Creuzenet
lab, identification was conducted on 9 GP candidates, which were the most abundant.
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One of the GP candidates was determined to be catalase, whose glycosylation had never
been reported before. The other GP candidates were presumed to be linked to LPS
biosynthetic enzymes, since PA mutants expressed altered or no O-antigens45. Through
further research with wild-type and PA mutants, it was concluded that there may be
several glycosylation pathways in H. pylori45.
Evidence of glycosylation of non-flagellar proteins in H. pylori was further
corroborated by another lab. Using a combination of metabolic glycan labelling
(supplementing the strain with peracylated N-azidoacetylglucosamine, Ac4GlcNaz,
leading to labelling of the N-linked and O-linked glycoproteins with azide), MS analysis,
and Western blotting, this lab was able to identify the existence of 125 putative GPs in H.
pylori70. These results revealed that GPs are abundant and widespread in H. pylori,
existing on the cell surface, inner and outer membranes, and within the periplasm and
cytoplasm70. This distribution suggests that protein glycosylation may be an essential
process of H. pylori’s physiology, with intracellular glycans potentially being involved in
stabilizing proteins and extracellular glycans stabilizing proteins and mediating host-cell
interactions70.
While these 125 proteins comprise those previously identified in the Creuzenet
lab, they do not comprise the outer membrane protein HopE that is the focus of this
study. One reason for this would be the nature of HopE glycosylation. Based on the sugar
chemistry of metabolic labelling, the GlcNac to be labelled would have to be on the base
of the polysaccharide structure. Although GlcNac in H. pylori is the initiating (base)
sugar in the process of LPS synthesis (and HopE glycosylation may happen by
attachment of this LPS O-antigen to the HopE protein), OSTs are usually specific for the
motif they recognize and transfer to the protein. Thus, the Lewis Y OST may not transfer
this single initiating base GlcNac, and there would be no guarantee that metabolic
labelling would aid in the identification of HopE.
Recently, using biotin-hydrazide labeling, anti-Lewis Western blotting, and silver
staining of outer membranes, our lab discovered that H. pylori strain NCTC 11637
contained a ~31 kDa Lewis Y glycoprotein. MS and enrichment by lectin affinity
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chromatography potentially identified this protein as the HopE porin that may be
glycosylated by a Lewis Y antigen. To confirm this, a hopE knockout mutant was
constructed, and anti-Lewis Y Western blotting of the outer membranes determined that
this ~31 kDa protein was present in the wild-type but absent in the knockout mutant. The
MS data also identified a putative glycopeptide that partially matched the amino acid
sequence of HopE, and which had 3 potential glycosylation sites: O-glycosylation on a
serine or threonine, and a N-glycosylation consensus sequence reading as Asn-Ala-Thr.
Modelling by Dr. Creuzenet (using the program Swiss-Prot against P. aeruginosa’s
OprH) indicated that this putative glycopeptide was localized on the surface of the outer
membrane, implicating its possible role in host mimicry, immune evasion, or adhesion to
host tissues (Figure 5).

Figure 5. Three-dimensional model of HopE.
HopE is likely glycosylated on the purple surface exposed loop as per preliminary mass
spectrometry data. Approximate boundaries of the hydrophobic regions of the proteins
predicted to be embedded in the outer membrane are represented by horizontal lines.
Modelled by Dr. Creuzenet.
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Hypothesis and objectives
Based on the above evidence, we propose that: The HopE porin in H. pylori plays a role
in antibiotic susceptibility, which may be influenced by HopE glycosylation with a Lewis
O-antigen transferred by the putative oligosaccharide transferase HP0946. Collectively,
this contributes to the pathogen’s virulence.
To address this hypothesis, we have three objectives:
1) Optimize the detection of HopE using anti-HopE antibodies to determine whether
HopE is glycosylated, via anti-Lewis Western blotting.
2) Investigate the role of the Lewis oligosaccharide transferase HP0946 in potential HopE
glycosylation and determine its connection to LPS synthesis.
3) Elucidate the functional impact of HopE and its putative Lewis glycosylation in regard
to antibiotic resistance/susceptibility.
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2

Materials and methods
Bacterial strains and growth conditions
All Helicobacter pylori NCTC 11637 strains were grown under microaerobic

conditions (5% O2, 10% CO2, and 85% N2) and 90% humidity in a tri-gas incubator
(NuAire) for 48 hours on Columbia agar (Fisher Scientific) plates supplemented with
7.5% sheep blood (Cedarlane), 0.05 µg/mL sodium pyruvate (BioShop), 5 µg/mL
trimethoprim (Sigma-Aldrich), 10 µg/mL vancomycin (Bio Basic), and 4 µg/mL
amphotericin B (Bio Basic); these are considered the “background” antibiotics. When
growing knockout strains, the agar was supplemented for selection with 5 µg/mL of
kanamycin (Bio Basic) and/or 12 µg/mL of chloramphenicol (Fisher Scientific). H. pylori
cells were stored as freezer stocks kept at -80°C in brain heart infusion yeast extract
(BHI-YE) media (EMD and Fisher Scientific) with 25% glycerol (Fisher Scientific) and
the appropriate antibiotics/supplement. After initial revival from a loopful of freezer
stock onto Columbia agar plates, the cells were spread onto a new plate via sterile loop
and grown for 48 hours. The confluent lawn was resuspended in BHI-YE broth with no
supplement or antibiotics and normalized to an OD600 of 0.2 before being spread to new
Columbia agar plates with no selection antibiotics via sterile cotton swabs. After 48
hours, the cells were harvested to an OD600 of 0.5 before downstream phenotypic
analyses. Table 1 shows the list of strains used in this study.
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Table 1. Helicobacter pylori strains used.
Strain

Gene(s) disrupted

Antibiotic

Made by

cassette
VJ WT

None

---

VJ ΔhopE

hopE

Chloramphenicol

MK WT

None

---

Used by V. Somalinga
K. Yogendirarajah
(in this study)
Used by M. KhodaiKalaki

BO ΔhopE
Δ946
ΔhopE/Δ946
ΔwaaL
ΔhopE/ΔwaaL

hopE

Chloramphenicol

946

Kanamycin

hopE and 946

Chloramphenicol

B. Oickle
J. Denomme

and kanamycin

K. Yogendirarajah
(in this study)

waaL

Kanamycin

A. Merkx-Jacques

hopE and waaL

Chloramphenicol

K. Yogendirarajah
(in this study)

and kanamycin

Escherichia coli DH5α cells were grown in Luria Bertani (LB) broth (BioShop) in
a 37°C shaking incubator at 133 rpm (New Brunswick Scientific) in standard
atmospheric conditions. The broth was supplemented with 100 µg/mL ampicillin (Bio
Basic) and/or selection antibiotics of either 34 µg/mL chloramphenicol or 30 µg/mL
kanamycin.

Membrane fractionation by differential solubilization
H. pylori cells were revived and subsequently grown and expanded to 20 plates of
confluent growth. Cells were re-suspended in 5 ml of 0.85% saline and lysed in a cell
disrupter (Constant Systems LTD IS6/40/BA/AA model) at 25,000 psi. Cellular debris
and unlysed cells were pelleted by centrifugation at 5,000 g for 20 min. The supernatant
was removed and ultracentrifuged for 1 hour at 100,000 g at 4°C to pellet membrane
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proteins (Optima-XL 100K ultracentrifuge, Beckman Coulter, TLA 110 rotor). The
recovered total membrane pellet was resuspended in 1 mL of 0.85% saline and
ultracentrifuged again for 1 hour under the same conditions as previously mentioned.
Then, the total membrane pellet was resuspended in 1 mL of solubilization buffer (50
mM sodium phosphate, 300 mM NaCl, pH 7.2) containing 1% w/v N-laurylsarcosine
(Sigma-Aldrich) and mixed on a nutator for 1 hour at room temperature and overnight at
4°C. The outer membrane was pelleted from the inner membrane via ultracentrifugation
at 100,000 g for 1 h at 4⁰C. The outer membrane pellet was mixed again with
solubilization buffer to further remove any leftover non-outer membrane components.
The final clean outer membrane pellet was resuspended in PBS (50 mM sodium
phosphate, 300 mM NaCl, pH 7.2) for protein analysis via SDS-PAGE.

Proteinase K digestion
For experiments that required complete protein degradation, outer membrane and
total membrane protein samples were digested with Proteinase K (PK). To 120 µL of
total protein samples, 5 µL of 20 mg/mL PK (BioShop) was added, while 30 µL of outer
membrane samples were supplemented with 2 µL of 20 mg/mL PK. Samples were
incubated at 60°C overnight to ensure completed digestion.

Western blotting and SDS-PAGE analysis
Bacterial cells were denatured with 1X SDS loading buffer (0.625 M Tris, 2%
SDS, 2% β-mercaptoethanol, 10% glycerol, 0.002% bromophenol blue, pH 6.8) and
incubated for 5 min at 100°C. The proteins were separated by SDS polyacrylamide gels
in the Laemmli system (Bio-Rad mini gel system). The gels used varied depending on the
application and included 12% bis-acrylamide gels (made in lab), bis-acrylamide stepwise gels (12% in the bottom third of the gel, 15% in the middle and 20% at the top;
made in lab), and pre-cast gradient gels (4-20% bis-acrylamide, Bio-Rad). Lab-made gels
were electrophoresed at 30 mA, while pre-cast gels were run at 250 V in 1X tris-glycine
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buffer (0.025 M Tris, 0.192 M glycine, 0.1% SDS, pH 8.3). Proteins and carbohydrates
were visualized either via silver staining or Western blotting. Proteins were occasionally
also visualized by Coomassie blue staining (10% acetic acid, 25% ethanol, 0.001% w/v
Brilliant Blue R-250 (Bio-Rad). Antibodies, lectin and Western blotting conditions used
are explained in Table 2.
For Western blotting, proteins were transferred to nitrocellulose membrane (BioRad) via wet transfer for 45 min at 180 mA in cold tris-glycine transfer buffer (25 mM
Tris, 192 mM glycine, 10% methanol, pH 8.3). After transfer, the proteins on the
membrane were visualized with Ponceau S stain (0.1% w/v Ponceau S (Sigma-Aldrich)
and 1% v/v acetic acid) for 2 min and washed with milliQ water. The membrane was
blocked for 1 hour with 10% skim milk with gentle shaking on the gel surfer (Diamed).
All further steps were performed with this gentle shaking. The membrane was then
washed twice with phosphate buffered saline (PBS) buffer (137 mM NaCl, 2.7 mM KCl,
8 mM Na2HPO4, 1.46 mM KH2PO4, pH 7.2) supplemented with 0.05% Tween-20 (USB
Corporation), and once in PBS buffer for 10 min each. Then, the membranes were
incubated with primary antibody for 1 hour. After incubation, the membrane was washed
as previously mentioned, then incubated with secondary antibody for 35 min in the dark.
The membrane was washed in the dark as stated above. Protein or LPS was visualized
using the Odyssey CLx imaging system (Li-Cor) at the wavelengths mentioned in Table
2.
Western blots were performed to screen aliquots of rabbit anti-HopE antibody
sera from different bleeds at different concentrations to determine optimal conditions for
future Western blotting. The outer membranes WT and ΔhopE samples were separated by
step-wise gels (with a single large well) and transferred to nitrocellulose membranes as
stated above. After transfer and Ponceau S staining of total protein content, the
membranes were cut length-wise into 7 identical strips and each strip was individually
blotted with the different bleeds (bleed #2, #3, #4) and the pre-immune serum. The strips
were then washed, blotted with the secondary antibody, and imaged as previously
mentioned.
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Table 2. Western blotting reagents used.
Epitope detected

Primary
antibody/lectin

Secondary
antibody

Wavelength
detection (nm)

HopE

Anti-HopE (1/200)
rabbit (ProSci)
[Custom ordered]

Goat anti-rabbit
IRDye (1/5000)
(Li-Cor)

800

Lewis Y

Anti-Lewis Y
(1/100) mouse
(Calbiochem)

Anti-mouse
(1/5000) goat
AlexaFluoro 680
(Invitrogen)

700

Fucose

BambL lectin
(biotinylated by the
Creuzenet lab)

Streptavidin
conjugated
AlexaFluoro 680
(Invitrogen) 1µg/mL

700

Silver staining of carbohydrates
The following silver staining protocol was created by Fomsgaard et al71. Briefly,
carbohydrates were first separated on an SDS-PAGE and then oxidized in a solution of
0.7% w/v periodic acid, 40% v/v ethanol and 5% v/v acetic acid in milliQ water with
shaking for 20 min. The oxidation was followed by five washes over 15 min in milliQ
water. The gel was then stained with silver nitrate (Fisher Scientific) in a staining
solution (0.19% v/v 10 N NaOH, 1.3% v/v ammonium hydroxide, 0.7% w/v silver
nitrate). Gels were stained for 10 min, followed by five washes over 15 min in milliQ
water. Following the wash, the gels were developed using 0.005% w/v citric acid and
0.05% v/v formaldehyde (37%) in milliQ water until bands became visible. The gels
were then washed several times with milliQ water and scanned.
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Chromosomal DNA extraction from H. pylori
Chromosomal DNA was extracted from total cell pellets using the
cetyltrimethylammonium bromide (CTAB) buffer (100 mM Tris-HCl, 1.4 M NaCl, 0.02
M EDTA, 1% w/v CTAB (BioBasic), pH 8.8) method. To the cell pellet, 500 µL of 1%
CTAB buffer and 500 µL of phenol:chloroform:isoamyl alcohol (25:24:1 v/v/v) was
added and vortexed to mix the solutions until an emulsion formed. This mixture was
centrifuged at 13,000 g for 5 min. The top aqueous layer was extracted and 500 µL of
chloroform-isoamyl alcohol (24:1) was added and centrifuged at 13,000 g for 5 min to
remove residual phenol. The top aqueous phase was recovered, and the DNA was
precipitated by adding 0.08 volume of chilled 3 M potassium acetate and 0.54 volume of
chilled isopropanol. The tubes with the mixture were inverted 30 times and incubated on
ice for 35 min. The DNA was pelleted by centrifugation at 13,000 g for 10 min at 4°C.
The DNA pellet was washed once with cold 100% ethanol, centrifuged as before, and
washed once again with cold 70% ethanol and air dried. The final DNA pellet was
resuspended in 50 µL of autoclaved TE buffer (50 mM Tris-HCl, 2 mM EDTA, pH 8)
and stored at 4°C.

Agarose gel electrophoresis
All PCR products were analyzed using 0.7% agarose gel prepared in TAE buffer
(40 mM Tris-acetate, 1 mM EDTA, pH 8.0). Samples were mixed with DNA loading
buffer (1X TAE buffer, 12.5% glycerol, 0.0025% bromophenol blue) before loading and
compared to a 1 kb DNA ladder standard (Invitrogen). Ten µL of ethidium bromide
(Invitrogen) were added to the gel tank before running the gel. Gel electrophoresis was
performed at 80 V for 30 min. DNA bands were visualized using UV light (254 nm) in
the Quantity One Chemidoc XRS system.
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Transformation of
NCTC11637 strains

pUC18/706KO

into

H.

pylori

The appropriate H. pylori strain was grown under microaerobic conditions as
described above and the cells were harvested into BHI-YE broth, pelleted at 4,000 rpm
for 10 minutes and washed twice in 0.85% saline, with centrifugation steps in between.
The cells were then adjusted to an OD600 of 0.5 in 0.85% saline. A total of 20 µg of
plasmid DNA was added to the cells to a final volume of 100 µL. A negative
transformation control consisted of 100 µL of cells with no plasmid incorporated. The
transformation mixtures were spotted onto Columbia agar plates supplemented with 7.5%
sheep blood, containing the antibiotics necessary for the original strain (WT or mutant
knockout) and cells were allowed to recover for 8 hours under microaerobic conditions at
37°C. The spots were resuspended in BHI-YE broth and plated onto Columbia agar
plates containing the appropriate antibiotics for selection using glass beads. Plating onto
Columbia agar plates with no antibiotics, to ensure viability after transformation, was
also done in parallel. These plates were grown for 5-7 days under microaerobic
conditions at 37°C until colonies were observed.

Minimum Inhibitory Concentration (MIC) E-strips
As mentioned in section 2.1, once the strains have been diluted to an OD600 of 0.5
in 0.85% saline, the suspension was spread with a sterile cotton swab onto Columbia agar
plates (with 7.5% sheep’s blood and no background/selection antibiotics or pyruvate).
Without re-dipping in the suspension, the plates were swabbed twice more after rotating
the plate 120° each time. After letting the plates dry for 2 min at atmosphere conditions,
the antibiotic E-test strip (Oxoid) was removed from its packet with clean forceps and
gently placed into the centre of each plate, being careful not to introduce bubbles between
the strip and the agar. Plates were incubated in microaerobic conditions in the 37°C
incubator for 48 hours. After incubation, the MIC was read off the strip.
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2.10 Disk diffusion assay
The antibiotic disks used in this assay were made in lab. Using a hole puncher to
create the disk shape, Bio-Dot SF filter paper (Bio-Rad) was cut and sterilized under UV
light. Once the appropriate concentrations of the clarithromycin antibiotic were
calculated, 10 uL of the solution was added onto the disks, dried, and stored at 4°C.
H. pylori strains were adjusted to an OD600 of 0.5 in 0.85% saline. The plates
were swabbed as per section 2.8 above and then left to dry for 2 min at atmosphere
conditions. Once dried, the plate was divided in half (one half per antibiotic concentration
to be tested) and the disks were placed with clean forceps in the center of the appropriate
section of the plate. After incubating the plate for 48 hours in microaerobic conditions at
37°C, the diameter of the zone of inhibition was measured using a ruler (in millimetres).

2.11 Immunoprecipitation of HopE
HopE polyclonal IgG antibodies immobilized to protein G agarose beads (Roche
Diagnostics) were used to pulldown and purify the HopE protein from the outer
membrane protein sample.
To prepare for binding, 400 µL of the beads were washed with 0.1 M sodium
phosphate buffer (PB) at pH 7.4, and were incubated with 100 µL anti-HopE rabbit
serum and 320 µL of 0.1 M PB at 4°C with agitation for 30 min. The beads were then
washed three times with 0.1 M PB. The protein G immobilized antibodies were washed
with 0.2 M triethanolamine (Sigma-Aldrich) buffer, which allows for the optimal
crosslinking activity of dimethyl pimelimidate (DMP). Cross-linking buffer containing
0.2 M triethanolamine and 22 mM of DMP (Sigma-Aldrich) was then added and allowed
to incubate for 45 min at room temperature. Next, 0.1 M ethanolamine (Fisher Scientific)
blocking buffer (pH 7.4) was added to quench the cross-linking reaction, and the solution
was left for 1 hour at room temperature with agitation to incubate. Finally, 1 mL of 0.1 M
glycine-HCl (pH 2.5) elution buffer was used to remove any non-cross-linked IgG
molecules from the protein G beads and immediately washed with 0.1 M PB after the
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beads settled to the bottom of the tube. The beads were washed twice with PB to clear the
beads of elution buffer and detached IgG molecules.
To further solubilize the partially insoluble VJ WT outer membrane sample in this
experiment, 240 µL of 0.1 M PB with 0.2% Triton X-100 (Mallinckrodt) was added to
160 µL of VJ WT outer membrane sample. The sample volume used for this experiment
was determined from previous Western blots that used the original OD600 of the VJ WT
outer membrane stock (which was 47.7 from 20 plates). The sample mix was incubated at
room temperature with gentle shaking for 30 min. The solution was ultracentrifuged at
100,000 g for 1 hour at 4°C and the supernatant was removed and diluted by half with
0.1M PB to a concentration of 0.1% Triton X-100. The leftover pellet was resuspended in
0.1M PB with 1.0% Triton X-100 and ultracentrifuged as before, and the supernatant was
diluted to a concentration of 0.1% Triton X-100. The pellet was kept and labelled “OM
unlysed”.
The lysed outer membrane mixture and the prepared anti-HopE protein G beads
were incubated overnight at 4°C with gentle agitation. To perform the pulldown, the
resulting protein and bead mix were transferred to a Nanosep 3K omega centricon tube
(Pall Corporation). This tube was used as separating the beads from the surrounding
solution proved difficult in the previous steps of this experiment, resulting in a minor loss
of beads each time supernatant was removed. It was expected that using a centricon tube
would prevent loss of beads as the solution could pass through the membrane unimpeded
and separate from the beads.
After the overnight incubation, the beads were then centrifuged as according to
centricon manufacturer instruction, at 13,000 g at 4oC for 15 minutes for the supernatant
to be removed. The supernatant was labelled “Unbound”. The beads were washed three
more times in 0.1 M PB containing 0.1% Triton X (to prevent aggregation and maintain
protein solubilization). Before the elution step, the beads were changed to a Nanosep 30K
omega centricon tube to allow the HopE protein to pass through the membrane and into
the filtrate receiver. To elute the HopE protein from the antibody complex, 100 µL of 0.1
M glycine HCl (pH 2.5) was added to the beads and the tube was centrifuged at 5,000 g

31

for 5 min at 4oC. The supernatant was recovered (“Elution”) and the acidity quenched
with an equivalent amount of 1N NaOH and checked with pH strips to ensure a neutral
pH. The elutions were analyzed on a Western blot.

2.12 Statistical analysis
Raw data was input into Graphpad Prism 6 software and all calculations including means
and standard errors and statistical analyses were performed using this software.
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3

Results

3.1 Optimization of the detection of HopE using anti-HopE
antibodies
Rationale:
Previously, using biotin-hydrazide labeling, anti-Lewis Western blotting, and
silver staining of outer membranes, our lab discovered that H. pylori (HP) strain NCTC
11637 contained a ~31 kDa Lewis Y glycoprotein. Mass spectrometry and enrichment by
lectin affinity chromatography potentially identified this protein as the HopE porin that
may be glycosylated by a Lewis Y antigen. To confirm this, a hopE knockout mutant was
constructed; anti-Lewis Y Western blotting of the outer membranes determined that this
~31 kDa protein was present in the wild-type but absent in the knockout mutant. The MS
data also identified a putative glycopeptide that partially matched the amino acid
sequence of HopE which had 3 potential glycosylation sites: O-glycosylation on a serine
or threonine, and a N-glycosylation consensus sequence reading as Asn-Ala-Thr.
Modelling by Dr. Creuzenet (Figure 5) indicated that this putative glycopeptide was
likely localized on the surface of the outer membrane, implicating its possible role in host
mimicry, immune evasion, or adhesion to host tissues.
However, at that time there were no antibodies to detect the HopE and verify if it
was HopE that was reacting to the anti-Lewis Y antibodies. To overcome this problem,
Dr. Creuzenet ordered rabbit antibodies (from ProSci Inc.) against a portion of HopE,
specifically a 15-amino acid sequence relating to a surface-exposed peptide loop:
GYKKFFQFKSLDMTS. This section of HopE was chosen for a several reasons. Firstly,
we needed the epitope to be from a portion of HopE that faced the outside of the cell, in
order to use this antibody for detecting the protein when subjected to whole cells. This
would be useful, for example, if the antibody is to be used to probe for interactions
between the HP and gastric cells. Secondly, the epitope also needed to be on an area that
was not near the location of the glycan, to prevent masking of that location if the Western
blot was re-probed with anti-Lewis Y. Lastly, this epitope was one of the few acceptable
locations that was found to be immunogenic according to in silico analysis.
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Results:
Two rabbits were immunized against this amino acid sequence (rabbit #1 and #2).
The ELISA titer results, obtained from the serum supplier, for the final bleed showed that
rabbit #1 had a lower ELISA titer than rabbit #2. Thus, we began working to optimize the
antibody detection of HopE on Western blot using the serum from rabbit #2 (Figure 6).

Figure 6. Timeline of polyclonal antibody production and ELISA results for both
rabbits.
Two pathogen-specific free rabbits were immunized with the HopE epitope multiple
times over a period of months. The ELISA titer results were quantified by ProSci and
compared the pre-bleed versus the final bleed for both rabbit sera. The red circle in the
ELISA table points out the larger antibody titer in rabbit #2.
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As we did not know which bleed would give us the best detection of the HopE
protein without much background signal, and at which dilution, we tested all bleeds at
various dilutions, ranging from 1/200 to 1/1000. The pre-immune serum was used as a
comparison against the three bleeds; it was not exposed to the HopE peptide so the
antibodies from the pre-immune serum should not react to HopE. We also only used
outer membrane (OM) samples (separated from the rest of the bacterial components using
ultracentrifugation and differential solubilization with N-laurylsarcosine), as we knew
HopE was an outer membrane porin, in order to minimize background signals and enrich
the protein of interest. To better resolve proteins of lower molecular weight (MW), we
created a stepwise gel and ran the OM samples of WT and the hopE knockout mutant
(Figure 7).
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Figure 7. Optimizing the anti-HopE antibodies for Western blotting.
The bacterial cells were lysed by mechanical disruption and the OM components were
separated via ultracentrifugation. Western blotting was performed on OM samples using
anti-HopE antibodies. The red horizontal lines mean the demarcation of transition from
20-16% and 16-12% acrylamide (the gel layout is shown at the top right). Left pink blots
are due to Ponceaus S red staining of proteins. The nitrocellulose membrane was cut into
strips and incubated separately according to the serum bleed and concentration. Red box
= protein band ~27 kDa that is non-reactive to pre-immune in WT and both pre-immune
and all bleeds in the hopE knockout mutant. The bottom right image depicts the current
final application of the anti-HopE Western blotting; red arrow denotes the location of the
HopE band. M = molecular weight marker.
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The red box in Figure 7 denotes a protein band smaller than 30 kDa that is not
reactive in the pre-immune stage but reactive in the bleeds in WT. This protein is also not
present in the hopE mutant blot. The bleed that was chosen to perform further anti-HopE
Western blotting was from the final bleed (bleed 4) at a concentration of 1/200. Based on
these experiments, HopE could be reliably detected using the optimized anti-HopE
Western blot conditions.
A vast number of protein bands were also reactive to these new HopE antibodies.
Thus, we investigated the reason behind this by comparing the peptide sequence used to
raise the antibodies against the OM proteins (OMPs) of HP. To date, we have compiled a
list (Figure 8) of OMP sequences that was obtained by blasting HopE against the HP
genome using the NCBI protein BLAST online tool. The results indicated that our
peptide sequence that we used for rabbit immunization (GYKKFFQFKSLDMTS) is
found in many OMPs, although with varying levels of conservation. However, this may
not be the cause of the cross-reactivity, as the naïve pre-immunized serum also has this
similar pattern of cross-reactivity (Figure 7). Nevertheless, the cause of this phenomenon
was not pursed further because these bands do not prevent us from detecting our protein
of interest.
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Figure 8. Complete list of OMPs that have similarities to the HopE epitope.
The green highlighted box indicates the location within the 28 non-HopE outer
membrane protein sequences that have a high degree of consensus with the HopE
epitope. The red amino acids are found within all the genes at that location, while the
blue amino acids are found within the majority of the genes at that location.
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All strains generated for this study
3.2.1 Initial strains available in the lab and problems encountered
Some of the original strains that had been ready for preliminary investigation
were a WT and a ΔhopE mutant derived from this WT, labelled Maryam Khodai (MK)
WT and Brandon Oickle (BO) ΔhopE mutant, respectively. Due to the repeated passages
of MK WT separate from its ΔhopE mutant, we could not be certain that the pair
remained isogenic. It was possible that because the WT was carried independently, phase
variation might have occurred, which concerns the LPS synthesis fucosyltransferase
genes. In order to standardize the Western blot and antibiotic testing results, the LPS
patterns of all the strains must be taken into account as they matter greatly when
interpreting the results of antibiotic sensitivity assays presented later, since the LPS can
play a role as a barrier to prevent intake of the antibiotic. Additionally, the LPS can also
cause interference in identifying Lewis Y or BambL reactive proteins and diminish the
observation of phenotypes that relate to proteins on the surface of the cell. Therefore,
finding or creating closely matching strains in terms of LPS patterns is important to
isolate phenotypes specifically due to HopE.

3.2.2 Generation of mutants relevant to this study
Rationale for VJ ΔhopE:
Since the MK WT had been passaged repeatedly by other lab members and may
suffer from phase variation that alters surface properties, the VJ ΔhopE was generated
during this thesis work using VJ WT as the recipient (Figure 9), therefore producing an
isogenic pair.
Results for VJ ΔhopE:
Transformation of the hopE knockout construct into the VJ WT strain resulted in
the production of 4 clones (Figure 9). Screening these clones via PCR and DNA
sequencing

indicated

that

several

clones

had

successfully

incorporated

the
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chloramphenicol resistance (CAT) cassette into the hopE gene, producing VJ ΔhopE.
Clone #2 was chosen to be the isogenic pair to VJ WT and its outer membrane was
extracted for subsequent analysis.

Figure 9. Creation of VJ ΔhopE.
The location of primers used for the analysis is shown in the schematic next to the gel
results. Succesful insertion of the hopE knockout construct was verified by the presence
of the hopE chloramphenical (CAT) resistance cassette (size of this PCR product would
be 1618 bp). Wild-type control without the cassette in hopE (- CAT) had a PCR product
size of 1463 bp. L = molecular weight standards.

Rationale for ΔhopE/ΔwaaL:
To better visualize the HopE protein and its potential Lewis glycosylation in
absence of LPS, we created the double knockout mutant ΔhopE/ΔwaaL by inserting the
hopE knockout construct into the ΔwaaL strain through natural transformation (Figure
10). With the O-antigen ligase function knocked out, there would be no fully formed LPS
structure although O-units of Lewis Y antigens would still be formed. Thus, it should
have no LPS-based Lewis Y reactivity while any glycoprotein-based reactivity would be
present during Western blotting. Additionally, this double knockout mutant would also
provide information on the function of HopE during assays to investigate its role, as
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removal of the LPS may provide greater access to the porin on the outer membrane. This
double knockout mutant would be compared to the reference strains ΔwaaL and ΔhopE
and is isogenic to ΔwaaL.
One caveat to mention is that if WaaL is responsible for HopE glycosylation by
transferring the Lewis Y onto HopE, then this double knockout mutant would not show
any difference of Lewis Y reactivity when compared to the single ΔwaaL mutant.
However, according to our hypothesis, the OST is not WaaL but is HP0946. We still
carried out systematic studies using the WT WaaL strains to ascertain if WaaL was
involved (Figure 10).
Results for ΔhopE/ΔwaaL:
Performing the transformation of ΔhopE/ΔwaaL resulted in the generation of 20
clones (Figure 10). The first ten were screened by PCR and their chromosomal DNA was
extracted. The resulting screening and DNA sequencing indicated that several clones had
successfully incorporated the chloramphenicol resistance (CAT) cassette into the hopE
gene and of these, clone #10 was selected for downstream applications. As such, we
proceeded to extract the outer membranes of this double knockout mutant clone.
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Figure 10. Generation of ΔwaaL/ΔhopE and the resulting PCR analysis.
The location of primers used for the analysis is shown in the schematic above the
corresponding DNA gels. A) The presence of the hopE chloramphenical (CAT)
resistance cassette increased size of the PCR product to 1618 bp. Lack of the cassette
resulted in a product of 1463 bp. B) Clones with the kanamycin (Kan) resistance cassette
in the correct location had a product size of 2958 bp. Strains without the kanamycin
cassette in waaL had a PCR product size of 2103 bp. L = molecular weight standards.

Rationale for ΔhopE/Δ946:
According to anti-Lewis Y and BambL Western blots (shown later, Figures 14
and 17), the LPS patterns of the WTs did not correspond well to the LPS patterns of the
ΔhopE mutants or the Δ946 mutant. This renders an accurate comparison between the
WT and the mutants difficult, as several of the assays performed in my project may be
affected by the composition/arrangement of the LPS pattern. However, the ΔhopE
mutants and the Δ946 mutant have similar LPS patterns (they have more abundant lower
molecular weight LPS molecules than the WTs in the anti-Lewis Y blots), thus it would
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be desirable to make a double knockout mutant using the Δ946 strain as the backbone in
which to incorporate the ΔhopE construct. In this manner, the double knockout mutant
can be compared to its respective single knockout mutants, using them as the reference
instead of the WTs which do not have a matching LPS pattern. Unlike the ΔhopE/ΔwaaL
double knockout mutant which does not have functional LPS pattern, this double
knockout mutant will still have LPS O-antigen and is isogenic to Δ946 (Figure 11).
Results for ΔhopE/Δ946:
After the transformation of ΔhopE/Δ946, 9 clones were obtained and their
chromosomal DNA was extracted and screened by PCR. All the tested clones showed a
PCR band consistent with the expected size. However, since the difference between the
clones and the controls without the CAT cassette are minimal and could not be resolved
on the agarose gel, DNA sequencing was performed. DNA sequencing indicated that
several clones had successfully incorporated the chloramphenicol resistance (CAT)
cassette into the hopE gene (Figure 11) and of these, clone #6 and #7 were selected for
antibiotic assays. Additionally, the outer membrane was extracted from this double
knockout mutant clone #7 and Western blots and silver staining (with Proteinase K
treatment) was performed.
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Figure 11. Creation of the ΔhopE/Δ946 double knockout mutant and the resulting
PCR analysis.
The location of all primers is shown in the schematic above the gel result. Presence of the
hopE chloramphenical (CAT) resistance cassette in hopE is indicated by the PCR product
size of 1618 bp. Absence of the CAT cassette in hopE is indicated by the product size of
1463 bp. The ΔhopE construct was transformed into the Δ946 mutant that had been
previously verified by another lab mate, Justine Denomme. L = molecular weight
standards.

3.2.3 PCR analysis of the LPS synthesis-related genes for phase
variation
Rationale:
In addition to ensuring that the various strains had the proper sequence in the
genes of interest, the fucosyltransferases FutA and FutC and the Wzk flippase genes
underwent PCR and sequencing analysis. The fucosyltransferases are enzymes required
for the production of Lewis antigens, as well as LPS chain length regulation and have
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highly phase variable regions in their genes31. The Wzk enzyme, while not phase
variable, is the flippase that transfers the O polysaccharide unit to the periplasm, where
the WaaL O antigen ligase attaches it to the lipid A core23. Thus, changes to these genes
could significantly affect the LPS structure of the bacteria, possibly resulting in
phenotypic changes such as a change in antibiotic susceptibility. However, the
fucosyltransferases are not the only genes with homopolymeric tracts that may potentially
inactivate their function. In fact, there are a total of 27 phase variable genes in all of HP72.
Results:
Analysis of the FutA, FutC and Wzk genes show no difference between the FutA
and Wzk sequences of all the strains; the enzymes were all in frame and therefore should
be functioning properly. The FutC gene was not in frame for most of the strains,
indicating that the full protein is likely not formed. However, it is likely that a truncated
form of FutC is still functioning, since the strains capable of making O-antigens are still
producing bands that react to Lewis Y (seen in anti-Lewis Y Western blotting). As FutC
is the only known enzyme in the LPS synthesis pathway that can create the Lewis Y
motif (see Figure 4), it is possible that since frame shifting occurs after the motif I, this
may be enough to perform the catalytic function of attaching the terminal fucose.

3.2.4 Analysis of the LPS of working H. pylori strains
Rationale:
In order to determine the LPS pattern of the various strains, samples were treated
with Proteinase K (PK) and subjected to silver staining. This procedure should eliminate
protein signals and allow the observation of each strain’s LPS profile. Additionally, it
could identify potential LPS present in the silver stain that is neither Lewis Y nor BambL
reactive. Sample loading was reduced as silver staining is a highly sensitive method that
does not require the same volume of sample input as the Western blots do.
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Although the OM preparations were made from normalized samples of the HP
strains (same optical density during harvest, same volumes used during OM extraction),
the volume of sample to use for these gels were refined using the Ponceau S stains of
Western blots to ensure that all the samples were loaded equally according to protein
content. Concurrently, a Coomassie stain to detect proteins was also performed with the
same samples to identify any proteins that may not have degraded completely during the
PK treatment and might be mistaken for LPS in the silver stain. Additionally, to identify
LPS patterns using anti-Lewis Y and BambL, the OM samples were digested with
Proteinase K and their LPS was detected via Western blotting.
Results:
The silver staining results (Figure 12A) showed that the ΔhopE and Δ946 mutants
had higher molecular weight silver-reactive bands (~31 – 40 kDa, indicated by a green
bracket), that are either undigested proteins or LPS. According to the Coomassie stain,
these bands are not proteins that were resistant to digestion as there is no Coomassie
reactivity in that area, thus they are likely LPS molecules. However, this silver response
was not seen in the WTs and ΔwaaL and ΔhopE/ΔwaaL double knockout mutant. As the
ΔwaaL and ΔhopE/ΔwaaL mutants do not have a functional O-antigen ligase, the lack of
this LPS is understandable. This is not as easily explained in the WT strains; the two WT
strains also had less lipid-A core than the other mutants. Thus, it is possible that despite
our best efforts at calculating to aim for equal loading, WT samples were loaded less than
the other strains. To determine if this was the case, silver staining was performed again
on new samples.
According to Figure 12B, the O-antigen products of the newly prepared OM
sample of the VJ WT strain was clearly visible unlike in Figure 12A. This indicated that
despite obtaining OM samples for all strains at similar optical densities with no changes
in the extracting of the OM component, there was still variations in the silver stain
response. It appears that OM samples weren’t precisely reproducible due to the likelihood
of variable O-antigen expression. The variation of HP’s O-antigen expression could also
affect antibiotic assays as the LPS plays a crucial role in repelling antibiotics. Thus, it
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was essential to perform 3 independent biological replicates for all antibiotics assays
conducted in this thesis. Figure 12B also provides a comparison of the newly extracted
ΔhopE/Δ946 double knockout mutant with its isogenic Δ946 mutant. No difference in
this LPS pattern was seen, as expected and antibiotic assays can be performed and
compared between these two strains and ΔhopE faithfully. Overall, ΔhopE does not
change the LPS pattern when comparisons are made with the properly matched isogenic
strains.
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Figure 12. Silver and Coomassie staining of Proteinase K treated samples.
OM samples were subjected to Proteinase K (PK) treatment and subsequently run on
BioRad precast gradient gels, 4-20%. A) One gel was developed with silver (left) and the
other with Coomassie (right). B) After staining the lipid-A core, the gel was cut along the
red dashed lines and re-stained with silver to expose the higher molecular weight bands.
Location of the LPS O-antigen is seen with the green bracket. Red star indicates location
of the lipid-A core. M = molecular weight markers.
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Results of the anti-Lewis Y and BambL blots showed the different LPS pattern
between the two WTs, making it clear that MK WT’s LPS profile appears to have been
altered in some way. This does not mirror the results of the silver stain, causing a
paradox. Silver staining is reportedly very sensitive, which is why less OM samples are to
be used when staining them with silver since they react so strongly. However, it is very
evident when comparing Figures 12 and 13 that the silver stain could not pick up the
higher molecular weight bands (greater than 40 kDa) seen using anti-Lewis Y antibodies
and BambL lectin. The reason for this was not investigated further at this point,
especially since MK WT had proved not to be isogenic to the BO ΔhopE mutant.

50

Figure 13. Visualizing the LPS pattern via anti-Lewis Y and BambL Western
blotting of PK treated OM samples.
OM samples were subjected to Proteinase K (PK) treatment and subsequently run on
BioRad precast gradient gels, 4-20%. The membranes were cut in half, one-half
incubated for anti-Lewis Y blotting and the other half for BambL blotting. Membranes
were also stained with Ponceau to visualize any undigested proteins. M = molecular
weight markers.

3.2.5 Analyzed characteristics of the working H. pylori strains
During the course of this thesis, the relevant characteristics of the working strains
were consolidated into a table (Table 3). The working strains used were VJ WT, MK WT,
VJ ΔhopE, BO ΔhopE, Δ946, ΔwaaL, ΔhopE/ΔwaaL, and ΔhopE/Δ946. As the table
illustrates, there appears to be no difference in the silver stain LPS pattern for isogenic
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strains with a functional waaL gene. However, there does appear to be differences in the
LPS pattern when visualized using PK treated samples in anti-Lewis Y and BambL blots
(Figure

13).

To

understand

the

reasoning

behind

this

phenomenon,

the

fucosyltransferases FutA and FutC and the Wzk flippase were analyzed via PCR.
Sequence analysis of the fucosyltransferase PCR products indicated that there were no
differences between the gene sequences of these strains that could explain the LPS
variation. Likely, this LPS variation is a consequence of other genes such as the
remaining 25 phase variable genes. It does appear that most genes do not have an “inframe” FutC gene. However, since the strains are reacting to the Lewis Y antibodies, it is
likely that the FutC gene is still functional by virtue of its most N-terminal transferase
domain that is in frame. Although ΔhopE/ΔwaaL’s FutC is in-frame, the deletion of the
waaL gene prevents LPS from being incorporated onto the outer membrane, thus it is not
relevant that FutC’s sequence in ΔhopE/ΔwaaL is different from the other strains since
the LPS result of FutC being in frame would not be observed. However, it is relevant in
terms of the nature of the O-antigen units that can be made and are available for
glycosylation.
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Table 3. List of features that have been analyzed for all working strains.

“Gene is not in frame” signifies that the strain is missing a 15th C base in the homopolyC
tract of FutC that would render the gene “in-frame”.
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Investigating HopE glycosylation with anti-Lewis Y
Rationale:
To determine the possibility of HopE glycosylation, the OM samples of several of
the strains were extracted and run on commercially produced precast 4-20% gradient
gels. These gels are the same as those used for LPS analyses described above in section
3.2 and were utilized to replace the home-made step-wise gels shown in Figure 7 in an
attempt to obtain more reproducible Western blots and defined protein/LPS bands to
allow for easier comparison between samples in a single blot and between two or more
different blots. Additionally, the use of these gradient gels may also allow easier
resolution of the HopE band away from the Lewis Y reactive LPS bands. When
performing this Western blot, half of the membrane was blotted with anti-HopE
antibodies while the other half was blotted with anti-Lewis Y antibodies.
Results:
In Figure 14A, comparing the lanes with strains containing HopE indicated by the
red arrows (VJ WT, MK WT, Δ946, ΔwaaL) to those with the hopE gene knocked out,
anti-Lewis Y signal intensity does not change (bottom panel) or even increases (top
panel). If HopE was truly glycosylated by a Lewis motif, the elimination of HopE should
result in a notable decrease in anti-Lewis Y signal in the ΔhopE mutants. This indicates
that HopE may not be glycosylated with Lewis Y. Additionally, the Lewis Y signal is
still present in the ΔhopE/ΔwaaL mutant in the HopE region, further indicating that
HopE is not glycosylated by Lewis Y. However, presence of Lewis Y reactive bands in
the ΔhopE/ΔwaaL and ΔwaaL mutants suggest the possible presence of other Lewis Y
glycosylated proteins, since the LPS O-antigen is eliminated from these two mutants.
In Figure 14B, the Western blots in Figure 14A were manipulated in Photoshop
by inverting the colours that appear when scanning the membrane (red wavelength
became blue, green wavelength became pink) to provide better visualization when these
blots were overlayed on top of each other. This analysis was performed to provide more
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proof of the possible lack of Lewis Y HopE glycosylation. If an anti-HopE reactive band
was also reacting to anti-Lewis Y, the band would show as purple.
However, these overlays did not work as well as they could have, due to
differences of migration of the samples in the lanes for the anti-HopE blot versus the
lanes for the anti-Lewis Y blot in the left panel. The VJ WT and the ΔwaaL lanes
experienced a slight lane distortion upward in the anti-Lewis Y blot but downward in the
anti-HopE blot, making it impossible to overlay the bands. In this blot, we can only
accurately compare the overlays of the middle two lanes (VJ ΔhopE and Δ946) as the
samples did not distort in either the anti-HopE or anti-Lewis Y blots. Therefore, the
HopE band in Δ946 coincides with a Lewis Y band, but that band is still present in the VJ
ΔhopE mutant, thus it is likely that the Lewis Y signal is not due to HopE glycosylation.
For the right-side panel, very little distortion was observed, making overlaying the two
blots possible. As there is still a blue Lewis Y reactive band in this ΔhopE mutant, these
inverted blots have the potential to provide further evidence that the Lewis Y reactive
band is not HopE.
Interestingly in the anti-Lewis Y Western blot, the Δ946 mutant exhibits a Lewis
Y pattern that is entirely different than the other strains. As the function of HP0946 is
unknown, complementation of this protein could confirm whether this altered Lewis Y
pattern is a product of eliminating HP0946. However, this was not attempted yet due to
time constraints.
To determine the specificity of the anti-HopE and anti-Lewis Y Western blot
results, blotting half the membranes with only secondary antibodies (Figure 15 and 16, “primary”) showed that the secondary goat anti-rabbit antibodies (that bind to anti-HopE
antibodies) and the secondary goat anti-mouse antibodies (that bind to anti-Lewis Y
antibodies) elicited very little cross-reactivity. The results of Figure 15 implied that there
is low non-specific binding by the secondary antibody. Similarly, the results of Figure 16
also indicated that the anti-Lewis Y Western blotting membranes blotted with both
antibodies were very specific and is likely only reacting with bands that contain Lewis Y
antigens.
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Figure 14. Ponceau S stain and Western blot to investigate HopE glycosylation by
Lewis Y.
A) Western blot of OM preparations detected with anti-HopE and anti-Lewis Y
antibodies on precast gradient gels (4-20%). Ponceau S stained membranes are shown on
the left to visualize proteins. The red dashed lines indicate that the ΔhopE and
ΔhopE/Δ946 mutants shown together were run on different gels at a later date to the rest
of the blot. Alignments were performed based on the molecular weight marker locations
and overlaying blots and matching the markers on both blots to each other. Sometimes,
non-specifically reacting protein bands on both blots are also aligned. Alignment via this
method is not always absolute as there are two separate membranes being used in which
warping can occur. B) Enhanced view of the two blots. The blots were inverted to obtain
the pink and blue colours using Photoshop in order to better visualize the bands when
they are overlayed on top of each other. The red arrow indicates the location of the HopE
band. M = molecular weight markers.
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Figure 15. Ponceau S staining and anti-HopE Western blot of OM samples to
determine antibody specificity.
Western blot of OM samples on gradient gels (4-20%), detected with freshly made antiHopE primary and secondary antibodies. Ponceau S stained membranes are shown on the
right to visualize proteins. M = molecular weight markers.
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Figure 16. Ponceau S staining and anti-Lewis Y Western blotting of OM samples to
determine antibody specificity.
Western blot of OM samples on gradient gels (4-20%), detected with freshly made antiLewis Y primary and secondary antibodies. Ponceau S stained membranes are shown on
the left to visualize proteins. M = molecular weight markers.
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Investigating HopE glycosylation with lectin BambL
Rationale:
Although HopE is likely not glycosylated by Lewis Y, this does not eliminate the
possibility that HopE is glycosylated with a non-Lewis Y glycan. To investigate this
possibility, a Western blot was performed with fucose binding biotinylated lectin BambL
and fluorescently labelled streptavidin. After blotting half of the membrane with this
BambL the blot was re-probed with anti-HopE antibodies to determine the location of
HopE; this strategy allows direct overlay of both blots. The original blots and enhanced
blots are shown in Figure 17.
Results:
Comparing the isogenic strains containing HopE in Figure 17 to the strains
without it (HopE is indicated by the red arrows), the BambL reactive band appears to be
lost when the porin expression is eliminated in the hopE knockout mutants. This is
particularly apparent on the blot overlays. Thus, HopE may be glycosylated by another
fucose carrying glycan.
Interestingly, removal of the HopE protein results in increased generation of
higher molecular weight fucose-containing bands (that are reactive with BambL) not seen
in the WT strains (indicated by the yellow brackets). The generation of higher molecular
weight BambL reactive bands is enhanced even more when eliminating the HP0946
protein, whose function is still unknown. Indeed, this phenotype is also seen in the double
knockout mutant ΔhopE/Δ946. It is likely that within the Δ946 mutant, the higher
molecular weight bands are Lewis Y O-antigens, as this BambL pattern is present in the
Lewis Y Western blots as well. Additionally, there is still BambL reactivity within the
HopE area for the Δ946 mutant, which is confirmed when comparing to the WT, ΔhopE
mutant and ΔhopE/Δ946 mutant. providing evidence that HP0946 may not be the OST
for HopE glycosylation. BambL reactivity also appears to be conserved in the ΔwaaL
mutant, therefore WaaL would also not be responsible for HopE glycosylation by the
BambL reactive motif.
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According to Figure 18, observing the BambL + streptavidin blots against the
streptavidin only blots shows there is very little non-specific binding occurring due to
incubation with streptavidin.
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Figure 17. Ponceau S staining and Western blotting with BambL to investigate
HopE glycosylation.
A) Western blot of OM preparations detected with BambL and anti-HopE antibodies on
BioRad precast gradient gels (4-20%). Anti-HopE antibodies were used to re-probe the
same membrane that had been incubated with BambL. Ponceau S stained membranes are
shown on the left to visualize proteins. The red dashed lines indicate that the ΔhopE and
ΔhopE/Δ946 mutants shown together were run on different gels at a later date to the rest
of the blot. Alignments were performed based on the molecular weight marker locations
and overlaying blots. Sometimes, non-specifically reacting protein bands on both blots
are also aligned. B) Enhanced view of the two blots. The blots were inverted to obtain the
pink and blue colours using Photoshop in order to better visualize the bands when they
are overlayed on top of each other. The red arrow indicates the location of the HopE
band. The legend at the bottom matches the colour of each outlined box to its respective
antibody/lectin. M = molecular weight markers.
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Figure 18. Ponceau S staining and Western blotting to detect non-specific binding
by BambL lectin.
Western blot of OM samples with BambL and streptavidin on gradient gels (4-20%).
Ponceau S stained membranes are shown on the left to visualize proteins. The “No
BambL” portion of the membranes were generated to visualize non-specific binding of
fluorescently labelled streptavidin. M = molecular weight markers.
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Immunoprecipitation of HopE to obtain target protein
Rationale:
To reduce non-specific binding of antibodies to non-HopE proteins and LPS and
to gain further evidence for/against the putative glycosylation of HopE, we aimed to
isolate the HopE protein and perform targeted Western blotting (anti-Lewis Y and antiHopE) without any interfering proteins or LPS. BambL Western blotting was also
performed to determine the possibility of HopE being glycosylated by another
fucosylated glycan.
Results:
Initially, the OM of VJ WT was lysed twice with the detergent Triton X-100; the
first time with 0.2% Triton X-100 and the second time with 1% Triton X-100. The first
lysate was then diluted by half to achieve an overall concentration of 0.1% Triton X-100
while the second lysate was diluted ten-fold before a sample was taken for gel analysis.
These dilutions were performed to ensure that the concentration of the detergent did not
affect downstream applications such as binding the lysate sample to the protein Gantibody mix.
The first lysate was incubated with the protein G-antibody mix because the
concentration of HopE within the first lysate was more concentrated. As it was unclear
how well the lysing with Triton X-100 would be in releasing HopE, the leftover insoluble
unlysed portion of the OM preparations was also kept and run on the 12% SDS PAGE
gel. The anti-HopE blot in Figure 19 shows that because HopE did not bind well to the
protein G-antibody linked beads, it eluted in the unbound and wash steps. The protein
that did elute in the elution step was roughly 50-55 kDa and is likely the heavy chain of
the IgG antibody. However, it did appear that there were less non-HopE proteins being
pulled down during this assay. There was not as many proteins reacting non-specifically
to anti-HopE antibodies and less non-HopE reactivity in the Ponceau S stain as compared
to the control lanes with OM samples of VJ WT and VJ ΔhopE. Thus, the blots are
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cleaner than the other Western blots done without this process and our goal for
performing this experiment was a success.
After blotting with the anti-HopE antibody, to determine the possibility of Lewis
Y glycosylation, the membrane was re-probed with anti-Lewis Y (Figure 19). As the antiLewis Y blot indicates, there is no reactivity to the HopE band. This provides further
confirmation that HopE is not glycosylated with Lewis Y.
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Figure 19. Immunoprecipitation of HopE results with Ponceau S, anti-HopE, and
anti-Lewis Y detection.
After the immunoprecipitation attempt to elute HopE protein, all fractions of the
immunoprecipitation assay were run on 12% SDS PAGE gels. Proceeding the Ponceau S
staining and probing with anti-HopE, the same membrane was then re-probed with antiLewis Y. The red arrow indicates the location of HopE. Under the larger blots, the area of
interest has been enhanced for easier visualization. M = molecular weight markers.
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BambL Western blotting was also performed and compared to the anti-Lewis Y
and anti-HopE blots (Figure 20). When the BambL and anti-HopE blots are examined
together, the HopE band appears to be reacting to BambL. This is quite evident when
viewing the OM control lanes for VJ WT and VJ ΔhopE; the HopE band clearly reacts to
BambL in the WT while the lack of HopE expression in VJ ΔhopE also results in the lack
of BambL reactivity in that area. This is significant considering that both samples were
loaded equally according to the Ponceau S stain. When comparing this to the unbound
and wash lanes, the BambL reactivity of HopE, although fainter than in the VJ WT
control, is visible. This provides further evidence to the idea that HopE is glycosylated by
a non-Lewis Y glycan that is fucosylated. Thus, glycosylation of HopE could still be
linked to the LPS pathway via the fucosyltransferases that would be involved in
generating this fucosylated glycan.
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Figure 20. Immunoprecipitation of HopE results with Ponceau S, anti-HopE, and
BambL detection.
After the immunoprecipitation attempt to elute HopE protein, all fractions of the
immunoprecipitation assay were run on 12% SDS PAGE gels. Proceeding the Ponceau S
staining and probing with BambL, the same membrane was then re-probed with antiHopE. The red arrow indicates the location of HopE. Under the larger blots, the area of
interest has been enhanced for easier visualization. M = molecular weight markers.
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Testing HopE’s role in antibiotic susceptibility/resistance
via antibiotic sensitivity assays
Rationale:
Etest strips and disk diffusion methods were utilized to discover significant
phenotypes amongst the ΔhopE mutants when compared to the WTs, ΔwaaL (in the case
of ΔhopE/ΔwaaL) or Δ946 (in the case of ΔhopE/Δ946). Performing both assays would
help solidify any phenotypic variations we see between strains, as the results should be
complementary to each other.
Results:
Table 4 shows the three different antibiotics that were used in this thesis. All three
antibiotics are of different classes, have differing sizes and function via different
mechanisms of action. This allowed us to observe the effect of HopE when subjected to
antibiotics with varying attributes.
The levofloxacin Etest results demonstrate that VJ ΔhopE performs similarly to
the WTs; removal of HopE sustains the same phenotype as VJ WT. Additionally,
removal of HopE in the ΔwaaL mutant maintains the ΔwaaL phenotype in the
ΔhopE/ΔwaaL mutant and removing HopE in the ΔhopE/Δ946 mutant keeps the Δ946
phenotype (Table 5). Therefore, eliminating the porin HopE does not affect the minimum
inhibitory concentration (MIC) compared with the original strains indicating that HopE
does not play a role in levofloxacin susceptibility.
When observing the results in the amoxicillin Etest, all strains have the same MIC
values except ΔwaaL and ΔhopE/ΔwaaL, with these two having the same lower MIC
(Table 5). Thus, HopE does not influence the susceptibility of H. pylori to amoxicillin,
similarly to the levofloxacin results. Overall, there is no significant difference between
the strains, as CLSI standards dictate that significance is noted only if MICs are 4-fold
dilutions apart.
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The ΔhopE mutants within the disk diffusion assay (Figure 21) did not elicit a
significant difference compared to the WTs, or the other background strains (ΔwaaL and
Δ946) in which the ΔhopE/ΔwaaL and ΔhopE/Δ946 mutants were made. This further
indicates that the HopE porin likely does not play a role in antibiotic susceptibility.
However, knocking out the HP0946 protein did result in greater susceptibility to
clarithromycin in the disk diffusion assay, in a similar level of susceptibility as the
ΔwaaL and the ΔhopE/ΔwaaL mutants.
With the loss of the full LPS barrier (specifically the O-antigen) against
antibiotics for the mutants ΔwaaL and ΔhopE/ΔwaaL, this explains their increased
susceptibility to antibiotics. However, this explanation can not be applied to Δ946, as the
strain still produces what appears to be the full LPS O-antigen as evidenced by the antiLewis Y and BambL blots. An alternative explanation is yet to be discovered. It would be
interesting to learn more about this protein in the future.

Table 4. Characteristics of antibiotics used for assessing antibiotic sensitivity.

The antibiotics used within this thesis are separated into several features. They all vary
significantly in most characteristics.
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Table 5. Results of the levofloxacin and amoxicillin Etest.

This Etest strip test was conducted on three different days with H. pylori strains grown
separately (N = 3). Cells were plated at a density of OD600 = 0.5. The brackets indicate
strains that are apparently isogenic and can be compared. The MIC values that are in a
range indicate that the strain varied in their response to the antibiotic once in the three
replicates that were performed.
25

10

µg/mL

µg/mL

Figure 21. Results of the clarithromycin disk diffusion assay.
The disk diffusion assay was completed three times (N = 3), one technical replicate per
each biological replicate, plated at a density of OD600 = 0.5. Mean ± SEM. Two-way
ANOVA with Sidak’s multiple comparison test, **** P < 0.0001.
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Identifying a strategy for HopE complementation in
ΔhopE mutant
Rationale:
Since the BambL reactivity seen in HopE is lost when HopE expression is
eliminated in the ΔhopE mutant, this is a phenotype that can now be verified via
complementation. The best method to date for performing complementation in H. pylori
is through chromosomal integration using suicide plasmids. While making the plan to
perform complementation, it was noticed that the suicide plasmids available in the lab
containing the full HopE gene had the same antibiotic selection cassette downstream of
HopE as the ΔhopE mutants (which were generated by disrupting the gene with a CAT
cassette). This is because they were originally created for integration of the glycosylation
point mutants of HopE in a WT strain. Thus, the antibiotic selection cassette would have
to be swapped to a kanamycin selection cassette in order to correctly screen for
transformants that had successfully incorporated the full hopE gene. However, swapping
the plasmids for a kanamycin cassette was more time consuming and did not fit into the
timeline of the project, thus it was not possible to complete this complementation in the
remaining time.
Instead of performing the full complementation, we tested if the HopE plasmid
complementation constructs obtained from previous lab mates would express the HopE
protein once transformed into the VJ WT strain. The lab has produced two plasmids
containing the full hopE gene. One is plasmid pMK35 from Maryam Khodai-Kalaki
(MK) that contains no His-tag but has a CAT cassette while the other is from Brandon
Oickle (BO) and contains a CAT cassette and a His-tag attached to the hopE gene. To
note, neither plasmid constructs contain a promoter region in front of the hopE gene.
Both are promoter-less genes that, once recombined in the chromosome in the hopE
locus, should allow expression of HopE from its endogenous promoter as per design.
Both plasmids were transformed separately into the VJ WT strain in an effort to
confirm that one of these constructs can be successfully incorporated into VJ WT and
produce functional HopE protein. The production and location of the HopE protein would

73

be assessed by Western blotting with anti-HopE and anti-His using the OM samples of
the two clones. If HopE is successfully expressed and observed in the Western blots, then
the process of swapping the CAT cassette for the kanamycin cassette and completing the
complementation can be undertaken in the future.
Result:
Transformation of the hopE genes followed by the CAT cassette with or without
the His tag was successful (Figure 22). Two clones were chosen for downstream analysis,
pMK35 706-His-less clone #1 and BO 706-His-CAT clone #5. The OMs of both clones
were extracted, and Western blotting was performed.
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A

B

Figure 22. Generation of the hopE + CAT strains in VJ WT.
A) The hopE-His-CAT integration sequence showing the location of each possible primer
available to use for PCR analysis. B) The location of the primers used to check the
integration of the correct sequence is shown in the schematic above the gel result.
Presence of the chloramphenical (CAT) resistance cassette and absence/presence of the
His tag was verified by the increase in product size. HopE = HP0706. L = molecular
weight standards.
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Analysis of the new OM sample preparations of pMK35 706-His-less and BO
706-His-CAT by Western blot using anti-HopE antibodies show that background signal
is observed in the lanes for these samples at a level similar to the ΔhopE mutant (Figure
23). As these plasmid constructs were transformed into VJ WT which has full HopE
protein expression, shown on the Western blot in Figure 18, this absence of HopE
expression indicates that the sequence of interest integrated into the correct location and
subsequently eliminated the existing HopE expression. Through sequence analysis of the
PCR product amplified using primers that span both upstream and downstream of the
region containing the hopE and CAT genes (706Tag2 and 706Tag9), the sequence of
hopE and the CAT cassette appear normal with no disruptions in their genes. However,
the next step in this project would be to use primers that are located outside the
recombination region and lie within the chromosomal DNA, such as 706Tag11 and
706Tag12. The resulting sequencing of these PCR products would provide information
about the genes upstream and downstream of the recombination junction and whether
they were affected in some that could give a reason for the loss of HopE.
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Figure 23. Analysis of HopE expression with Ponceau S staining anti-HopE Western
blotting.
Western blot of OM samples run on 4-20% precast gradient gels. Ponceau S stain on the
right. OM samples were loaded onto the gel in two concentrations, the lower and higher
one. Loadings for each sample was defined by previous analysis with Coomassie staining
after OM samples were prepared. The red arrow indicates the location of HopE. The
enhanced section of interest in the blot is shown below. M = molecular weight markers.
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Chapter 4: Discussion
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4

Discussion
New anti-HopE antibodies successfully detect the HopE
protein
Prior to the onset of my research into HopE glycosylation, there were no

commercially available anti-HopE antibodies. My predecessors who had worked on this
project had established the possibility that HopE might be glycosylated by Lewis Y using
MS analysis and Western blotting. To connect the Lewis Y reactivity to HopE, custommade anti-HopE antibodies were ordered using a predicted extracellular peptide of HopE
with the amino acid sequence of GYKKFFQFKSLDMTS.
After obtaining the sera of two HopE immunized rabbits and determining the final
ELISA results, rabbit #2’s antibody sera was used as it had the higher antibody titer
(Figure 6). However, there were several bleeds that were obtained during different
timepoints within the immunization schedule of the rabbits. Thus, determining which
bleed to use for successful detection of HopE was the priority. Using a step-wise gel with
decreasing acrylamide concentration and extracting the outer membrane (OM) of the WT
and hopE knockout strains using differential solubilization with N-laurylsarcosine, it was
observed that all bleeds efficiently detected HopE. Using the Western blot (Figure 6) and
the ELISA titer data, the final (fourth) bleed of rabbit #2 was utilized at a concentration
of 1/200 for future experiments.
The use of the step-wise gels, while appropriate for ascertaining the working antiHopE antibody concentration as seen in Figure 7, was not efficient at resolving the HopE
protein from other proteins/LPS bands that were reacting to Lewis Y and co-localizing to
the same area as HopE. After multiple attempts to further resolve HopE from non-HopE
Lewis Y-reactive proteins/LPS bands in these step-wise gels, it was decided that gradient
gels may be the best solution for this recurring issue. Thus, precast gradient gels (4-20%)
were purchased from BioRad. In Figure 7, the results obtained by the precast gels can be
seen. The gradient gels could effectively condense and resolve the proteins and LPS into
distinct bands, allowing for greater protein comparability between lanes within the same
blot and within different blots. The use of commercially produced gradient gels also
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allowed for highly reproducible and standardized blots, with proteins running to the same
location every single time.

HopE glycosylation in Helicobacter pylori
With the discovery of a ~31 kb protein that reacted to anti-Lewis Y in our lab, MS
analysis suggested that the protein was possibly HopE. However, with the acquisition of
working anti-HopE antibodies, this idea could be verified for certain. To aid in the
identification of HopE as a glycoprotein, the double knockout mutant ΔhopE/ΔwaaL was
successfully generated to observe the HopE protein without interfering LPS structures in
both Western blots and functional assays. Nevertheless, it was important to consider that
this ΔhopE/ΔwaaL mutant does have the potential to abrogate glycosylation if WaaL
serves as the oligosaccharide transferase (OST). If WaaL was not the OST, the synthesis
of O-units would still be preserved and could be transferred onto HopE by the true OST,
such as HP0946.
From examining the results of the anti-HopE and anti-Lewis Y blots (Figure 14),
it is evident that the reactivity of the Lewis Y antibodies in the area of HopE does not
change in response to the loss of the HopE protein in the ΔhopE mutants (in WT or in the
ΔwaaL background strains). This is likely because HopE is not glycosylated by Lewis Y.
However, one caveat to mention is that as there appears to be a strongly reacting band to
Lewis Y in the same area as where the HopE localizes, and this might mask the loss of
Lewis Y signal if HopE was glycosylated with Lewis Y. It is likely, according to MS
data, that HopE would only have one unit of Lewis Y motif, thus it might not be easily
detected by the Lewis Y antibody so its loss in the ΔhopE mutants would not be visible
when compared to the other proteins/LPS also reacting in that area. Objective 2 of the
hypothesis was to determine if the HP0946 protein is the Lewis oligosaccharide
transferase (OST) for HopE glycosylation. These series of blots determined that HP0946
is not the OST for HopE Lewis Y glycosylation. This is evidenced by the lack of any
changes to the Lewis Y reactivity in the HopE area for the Δ946 mutant.
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Conversely, the BambL blots (Figure 17), that detect fucosylated epitopes which
include Lewis Y but also non-Lewis Y epitopes, showed the opposite. When HopE
expression was eliminated, it appeared that BambL reactivity was also absent. Thus, there
is evidence that HopE may be glycosylated by a non-Lewis Y glycan. However, like the
anti-Lewis Y blot illustrated, the Δ946 mutant still had BambL reactivity in the HopE
area, meaning HP0946 is not an OST for the HopE protein. With this result, it is
important to try to elucidate both the identity of the non-Lewis Y glycan and the identity
of the OST responsible for transferring the glycan to HopE.
To note, Figures 15, 16, and 18 show the results of testing for non-specificity
from the secondary antibody. The results illustrate that although all blots, especially the
anti-HopE blot (Figure 14), have multiple bands, these bands are not due to non-specific
binding by the secondary antibody. The multiple bands seen on Figures 14 and 17 when
using both primary and secondary antibodies/lectin are likely due to the antibody/lectin
reacting to proteins/LPS that contain the epitopes of interest.
Additionally, eliminating HP0946 expression causes the generation of higher
molecular weight bands that are reactive to both Lewis Y and BambL. This is evidenced
when comparing the Proteinase K treated samples in the anti-Lewis Y and BambL
Western blot in Figure 13 to the blots in Figure 14 and 17. Currently, there are a couple
unknown aspects of this discovery, such as whether these bands are LPS or proteins and
the function of HP0946. However, since HP0946 is localized to the inner membrane, it is
entirely possible that eliminating this protein may indeed affect the LPS synthesis
pathway as most of the proteins involved in that pathway are also found within the inner
membrane. Again, a complete answer for this phenotype is yet forthcoming.
The discovery of an outer membrane protein with an unknown fucose-containing
glycan signifies the importance of molecular mimicry in H. pylori. Although it is not
Lewis Y, as a fucose-containing glycan it may still be Lewis X, Lewis a or Lewis b,
which are human blood group antigens73.
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Variations in LPS pattern for different H. pylori strains
To achieve further observation of the LPS pattern in the working strains, PK
treated OM samples were visualized using the silver staining method. Treating the OM
samples with PK should effectively digest the protein content and leave the LPS
molecules intact. In the silver stain of Figure 12, there is a discrepancy in the LPS pattern
when comparing the WTs and ΔwaaL mutant and ΔhopE/ΔwaaL double knockout
mutant to the ΔhopE and Δ946 mutants. The WTs and ΔwaaL mutant and ΔhopE/ΔwaaL
double knockout mutant do not have the higher silver-reactive bands (~31 – 40 kDa,
indicated by a green bracket) that are seen in the ΔhopE and Δ946 mutants. Initially, it
was assumed that this was evidence for a variation of the LPS between the WTs and the
ΔhopE and Δ946 mutants. The results of the waaL and ΔhopE/ΔwaaL mutants are as
expected since these strains do not have the O-antigen ligase therefore they would not
have a full LPS pattern. Additionally, it was confirmed that the lanes containing OM PKtreated samples from the ΔhopE and Δ946 mutants do have higher silver-reactive bands
that are likely LPS and not proteins. This was verified by the concurrently performed
Coomassie stain, which does not show those bands, indicating they were not protein
bands that were PK resistant.
However, the WT strains also had less lipid-A core concentrations in the Figure
12 silver stain, implying that although every effort was taken to aim for equal loading, the
WT samples may not have been loaded as strongly as the other strains. Thus, another
silver stain was conducted with freshly extracted WT OM samples and the new OM
samples of ΔhopE/Δ946 mutant. As Figure 13 clearly demonstrates, despite our best
efforts to ensure equal loading in Figure 12, there was a loading issue for the WTs that
resulted in the low visibility of the higher LPS molecules via silver stain. In fact, the best
way to visualize the higher LPS molecules was to cut out that area and re-stain with
silver.
This variation in O-antigen expression between each OM extraction could also
play a role in influencing each individual antibiotic assay, making it very important to
have replicates of each assay, regardless of how reproducible the tests reportedly are
(such as the Etest). To summarize, both silver staining and Coomassie results indicate
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that the LPS molecules seen in the 31-40 kDa range are present in all the strains and do
not change depending on a specific mutant.

Immunoprecipitation
glycosylation

of

HopE

to

identify

HopE

To definitively determine the presence/absence of HopE glycosylation,
production of cleaner Western blots without interfering proteins or LPS was attempted.
Therefore, purification of HopE through immunoprecipitation was required. However,
the protein HopE is part of the insoluble outer membrane section of HP, rendering the
outcome of conventional immunoprecipitation assays to purify HopE uncertain.
In an attempt to make the insoluble OM portion more soluble and subsequently
release the HopE protein into the soluble supernatant, the OM sample of VJ WT was
subjected to lysing via Triton X-100, a non-ionic detergent. As the effectiveness of this
attempt remained unclear, the OM sample was lysed twice, first with 0.2% Triton X-100
and diluted by half in buffer solution and the second time with 1% Triton X-100 and
diluted ten-fold. However, only the first lysis was subjected to immunoprecipitation since
it would have the higher concentration of soluble HopE protein.
After running all the immunoprecipitation fractions on an anti-HopE Western blot
(Figure 19), it was evident that although the blot was cleaner and contained less proteins,
the HopE protein had not bound well to the protein G-antibody linked beads. The reason
for this is likely due to the pH of the buffer containing dimethyl pimelimidate (DMP), the
cross-linking reagent, being below pH 8. If the pH of the solution falls below 8, or rises
above 9, the cross-linking efficiency of DMP is greatly reduced74. However, the pH of
the solution was 7.42 in response to the isoelectric point of HopE being 8.86, since the
efficient functioning of the sodium phosphate buffer requires its pH to be at least 0.5 pH
units away from the isoelectric point of the HopE protein. Thus, the DMP was not
effectively cross-linking the antibody to the protein G beads, resulting in a weak bond
that could easily dissociate and elute early the antibody and the HopE protein. One future
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direction to obtain better immunoprecipitation results would be to increase the pH of the
buffer solution to around pH 8.3; this should allow DMP to work effectively. Regardless
of this low cross-linking efficiency, immunoprecipitation was still a success as it reduced
non-HopE protein and allowed for more targeted Western blotting assays to be
performed.
After confirming the presence of the HopE proteins in the immunoprecipitation
fractions using anti-HopE antibodies, the membrane was re-blotted with anti-Lewis Y to
determine the potential for Lewis Y glycosylation. As in previous anti-Lewis Y Western
blots shown in this thesis, the cleaner Western blot showed that Lewis Y was not reactive
to HopE (Figure 19). This is the best proof that HopE is not glycosylated by Lewis Y.
However, the reactivity of BambL to HopE seen in Figure 17 indicates that while HopE
may not contain the Lewis Y glycan, it does appear to be glycosylated by a non-Lewis Y
glycan that contains fucose. Previous research conducted by other labs has shown that HP
NCTC 11637 also contains H-type O-antigens75 and BambL has shown to bind
preferentially to H-type glycan compared to Lewis Y76. Thus, it is possible that the
glycan in question is an H-type, which only contains the fucose on the terminating end of
the O-antigen.
The putative glycosylation of HopE aligns with porin glycosylation in previous
literature. Currently, there are only two well-established porin glycoproteins: C. jejuni’s
major outer membrane protein (MOMP)63 and P. aeruginosa’s OprD64. However, among
the three porins, glycosylation occurs using differing glycans, whereby the MOMP is
glycosylated with one galactose and three GalNAc residues, OprD contains 3 sialylated
N-glycans and 2 sialylated O-glycans, and HopE is glycosylated with a fucose-containing
glycan. Importantly, the glycosylation of MOMP was observed to occur at T268, which is
in a surface exposed loop as was found in HopE. In this thesis, the role of HopE and its
glycosylation in antibiotic resistance was studied, as porin OprD plays a role in antibiotic
susceptibility64. As evidence shows that HopE is likely glycosylated, one future direction
(once complementation has established HopE as a glycoprotein) could be to study the
role of HopE’s glycosylation in other processes such as those studied in MOMP.
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Glycosylation of this MOMP porin indicated a correlation to promoting bacteria-tobacteria binding, biofilm formation, and adhesion to Caco-2 cells.

The HopE porin likely does not play a role in antibiotic
susceptibility
Previous research into other porins have implicated porins as a passage for
antibiotics into the cell15,77, such as Escherichia coli’s OmpC78, Acinetobacter
baumannii’s OmpA79, and Vibrio cholerae’s OmpU80. Additionally, it was also shown
that sialylation of the porin OprD of Pseudomonas aeruginosa resulted in decreased
uptake of β-lactam antibiotics through this porin64. Thus, the possibility that HopE and its
putative glycosylation play a role in antibiotic resistance was explored via the use of
several antibiotics and multiple antibiotic sensitivity assays.
Table 3 lists the various types of antibiotics used, each with a different
mechanism of action to target various processes within the bacterial cell. These three
specific antibiotics were also chosen due to their clinical relevance, as they are all used in
triple and quadruple therapy treatments to combat HP infection10. Using these antibiotics,
different antibiotic sensitivity assays were employed, including spot plating, gradient agar
plate method, E-tests and disk diffusion assays. Each assay was meant to complement
one another; however, not all the assays lead to reproducible results.
The spot plating method is a long exposure test conducted by incorporating the
test antibiotic into blood agar media and observing the growth of the bacteria. As we did
not know which specific concentration of each antibiotic would be effective at
differentiating the strains, three different concentrations for all antibiotics used were
tested (data not shown). To note, the strains were grown on solid media instead of a broth
because HP does not grow well in broth. HP simply survives, which is not adequate for
antibiotic sensitivity testing as several antibiotics target peptidoglycan growth and protein
synthesis, so the bacteria need to be actively growing. Once the proper optical density
was achieved, the cultures were serially diluted 10-fold for 8 dilutions and spot-plated on
the antibiotic-incorporated plates. Two strains were tested on one plate with one
antibiotic at a specific concentration. Thus, a single strain was tested on three
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concentrations of one antibiotic, plus a control containing just the background antibiotics
usually used and no test antibiotic. Once the bacterial colonies had grown well enough to
count them, the CFU/mL was calculated and compared among strains. Results from
multiple trials of this assay proved to be inconsistent and the colonies were hard to count
accurately. This assay was also not as high throughput as was required to test the large
number of strains that were studied within this thesis; thus, the spot plating method was
set aside.
As another method of testing antibiotic sensitivity, the strains were grown on
antibiotic gradients via the gradient agar plate method (data not shown). In this assay, the
plates are manually created and the initial antibiotic used was clarithromycin, as it was
the most promising antibiotic that gave differences between the strains in the spot plating
method. The plates are laid out on a slant and the agar containing the test antibiotic is
poured into the plate. After this layer cooled down, that plates were placed back on level
surface and agar with only background antibiotics were poured. Once cooled, the plates
were flipped upside down and the antibiotics began to diffuse, thus establishing a
gradient of antibiotic concentration. According to literature, as antibiotics can diffuse in
the plates, the plates should be used not too long after the 12 hour mark81. The HP strains
are then spread via sterile glass beads on the gradient plates and the control plate (no
gradient, no test antibiotic) and incubated for 16 hours. Results of this method showed
that there were no discernible changes in growth density across the gradient plates. It was
decided that this method may not be the best assay for a slow growing organism, as the
antibiotic gradient may be lost before it can successfully affect HP growth, which would
especially be a problem if the antibiotic was bacteriostatic. This assay was abandoned
after two trials.
Following the failure of the spot plating and gradient agar method, Etest strips
were purchased for levofloxacin and amoxicillin. Etest strips are considered the gold
standard for testing the response of bacteria to antibiotics in clinical laboratories. The
strips also generate highly reproducible results, are easy to use, and are high throughput.
At the time, commercial strips for clarithromycin were unavailable so the disk diffusion
assay was implemented for this antibiotic.
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Considering the results of the levofloxacin Etest, most strains did not react
significantly different to each other, including the WTs and VJ ΔhopE (Table 5). This
provides evidence that eliminating HopE expression does not cause an increase in
susceptibility or resistance. This was further proven by the double knockout mutant
ΔhopE/ΔwaaL, which was initially created to compare against the ΔhopE and ΔwaaL
mutants. As the LPS O-antigen is lost in this double knockout, this loss should allow the
antibiotics to have clearer access to the HopE porin without the steric hindrance provided
by the LPS molecules on the outer membrane. However, it appeared that any increase in
susceptibility that this double knockout mutant exhibits could be attributed to the
phenotype caused by the elimination of the O-antigen ligase WaaL as can be seen in the
single ΔwaaL. Furthermore, contrasting the longer BambL- and Lewis Y-reactive LPS
pattern seen in the VJ ΔhopE mutant (Figures 14 and 17) with the shorter one observed in
VJ WT also indicated that this variation in LPS does not affect the way these two strains
interact with levofloxacin, which aligns with the silver stain gel (Figure 13) that shows no
variation in the LPS. These results are also mirrored in the amoxicillin Etest results.
The purpose of the ΔhopE/Δ946 mutant was to eliminate HopE expression in a
strain that had LPS matching the LPS of the ΔhopE mutant. This was effective, and the
LPS pattern of the ΔhopE/Δ946 mutant remained the same as its respective single
mutants. Through the successful generation of the ΔhopE/Δ946 mutants, there is further
evidence that eliminating HopE does not change the susceptibility of the ΔhopE/Δ946
mutant to levofloxacin or amoxicillin compared to the single Δ946 mutant. This same
outcome was also seen in the antibiotic sensitivity results for ΔhopE/ΔwaaL in that
eliminating HopE didn’t affect how ΔhopE/ΔwaaL reacted to the antibiotic compared to
the ΔwaaL mutant.
To overcome the lack of clarithromycin Etest strips, this assay was performed by
adding two different concentrations of clarithromycin to separate homemade disks and
placing the disks on a lawn of bacteria, similar to the Etest. This method, while cheaper
than the Etest strips, was slightly more time consuming and required some trial and error
to get the right working concentrations of antibiotics to obtain readable zones of
inhibition. However, the results of this test were very reproducible, and the method
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allowed for higher throughput as multiple disks of different antibiotic concentrations
could be placed on a single plate with the bacterial lawn. As Figure 21 demonstrates,
when comparing the WTs to the Δ946¸ ΔwaaL and double knockout mutants, the results
of this assay closely resembled those of the Etest disks and were more highly visual.
Again, ΔhopE mutants did not vary from the WTs, similar to the Etests.
Collectively, all these antibiotic tests show that eliminating HopE does not cause
a significant difference when matching the mutant to its isogenic strain (be it the WT
strain, ΔwaaL mutant, or Δ946 mutant) for either levofloxacin, amoxicillin or
clarithromycin. HopE does not play a role in antibiotic susceptibility. Interestingly, the
results of the disk diffusion method showed that eliminating HP0946 increased the
susceptibility of the Δ946 strain to clarithromycin; the results were significantly different
compared to the WT strains and similar to the ΔwaaL and the ΔhopE/ΔwaaL mutants
which are lacking the full LPS structure. As seen in the anti-Lewis Y and BambL blots,
the Δ946 mutant has its full LPS therefore an alternate explanation must be discovered.
Very little is known about this protein, which has been annotated as a sodium-proton
antiporter but never confirmed. One hypothesis is that perhaps HP0946 is involved in
either preventing entry of antibiotics across the inner membrane or may be involved in
extruding antibiotics back to the periplasm.

Working towards a functional complementation strategy
to restore hopE expression in the ΔhopE mutant
Through the elimination of HopE expression, it was discovered that WT strains
contain a BambL-reactive band in the HopE protein region that is lost in the hopE
knockout mutants, implicating the existence of HopE as a fucose-containing
glycoprotein. To verify that this is a robust phenotype, complementation would be the
next step of this project. However, due to the suicide plasmids with full HopE constructs
containing the same selection cassette as the hopE mutants, swapping the selection
cassette to kanamycin was beyond the timeline of my project. Thus, to ensure that the
plasmids containing the full hopE gene would successfully integrate into the knockout
mutant and allow expression of the HopE protein, these HopE promoter-less plasmids
pMK35 706-His-less and BO 706-His-CAT were separately transformed successfully
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into VJ WT. The purpose of the histidine tag within the clone created by BO was in an
attempt to tag and purify the HopE protein as purification of proteins using affinity
chromatography with nickel targeting the His tag had been proven to provide high protein
yields and purity of over 95%82. This tag was added to the C-terminus of the protein to
prevent its removal when the N-terminal signal sequences of the protein is cleaved during
transport into the periplasm83. Subsequent nickel affinity chromatography did not detect
His tagged HopE in the outer membrane fractions. It was assumed that this method for
identifying His tagged HopE proteins was ineffective given the circumstances or that the
His tag may prevent proper folding and OM localization of HopE. However, at the time
of the creation of this His tagged HopE, there were no anti-HopE antibodies to confirm
that His tagging might have altered HopE protein expression itself.
Two of the resulting clones from each set of transformations were analyzed via
PCR using primers that spanned the length of the gene sequence of interest (Figure 22),
706Tag9 annealed within the integrating construct while 706Tag2 annealed to the
chromosomal DNA downstream of the region of recombination. The sequencing data
indicated that both the hopE gene and the CAT cassette gene had successfully
incorporated into the VJ WT genome without mutations and that the sequence inserted
into the correct area. Therefore, the outer membranes were extracted from one clone from
each transformation and subjected to anti-HopE Western blotting.
Comparing the WT, ΔhopE, pMK35 706-His-less and BO 706-His-CAT samples
to each other indicated that incorporation of the new hopE gene sequence into the VJ WT
eliminated the expression of HopE entirely, similar to the ΔhopE mutant. This
elimination also indirectly confirmed that the plasmids had recombined correctly and
inserted the sequence into the right area. One of the reasons for this lack of HopE protein
expression could be due to the His tag attached to the HopE protein. Perhaps the His tag
prevented proper folding of the HopE protein, resulting in the protein being degraded and
prevented from being exported to the outer membrane. Conversely, the pMK35 706-Hisless clone should not have a functional His tag and sequence analysis showed that the His
sequence is still there with a stop codon placed before it to prevent its translation. Lack of
HopE expression in this clone indicated that either the stop codon and His sequence still
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resulted in disrupting HopE expression, perhaps because of mRNA instability, or
something else unrelated to the His tag DNA sequence was the cause of the loss of
protein expression. It may be possible that integration of this sequence causes gene
disruptions either upstream or downstream of the integration area.

Summary and future directions
To re-iterate, the objectives of this project were:
1) Optimize the detection of HopE using anti-HopE antibodies to determine whether
HopE is glycosylated, via anti-Lewis Western blotting.
2) Investigate the role of the Lewis oligosaccharide transferase HP0946 in potential HopE
glycosylation and determine its connection to LPS synthesis.
3) Elucidate the functional impact of HopE and its putative Lewis glycosylation in regard
to antibiotic resistance/susceptibility.
To highlight objective 1, this study demonstrated the presence of HopE as a novel
glycoprotein that is glycosylated by a currently unknown glycan containing fucose. This
was done in part through the successful optimization of the anti-HopE antibodies,
regardless of the serum’s propensity to cross-react with non-HopE OM proteins with
similar epitopes to the porin. Although initially it was thought that the glycan was Lewis
Y, after comparing the anti-Lewis Y blots with anti-HopE, it became clear that this was
not the case. Through the use of the BambL lectin, it was determined that the glycan did
contain a fucose (like Lewis Y) but was another as yet unidentified glycan.
As a result, a future direction of this study is to further characterize this HopE
glycoprotein and determine the glycan with which it is glycosylated. The next step in this
characterization would be to develop strategies to specifically purify for HopE and other
glycoprotein candidates that react to BambL. In this case, affinity for the BambL lectins
can be utilized to purify for glycoprotein candidates from the unmodified proteins. For
this method, BambL lectin could be coupled to a matrix containing sepharose.
Subsequently, the BambL lectin can be used to purify the fucose-modified glycoproteins
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(including HopE) via affinity chromatography. Once purified by this method, the
glycoprotein candidates can be sent for MS analysis for identification of the proteins and
the glycan itself.
Nevertheless, the results of this thesis also indicate that contrary to our hypothesis
for objective 2, HP0946 is not the OST that glycosylates HopE as the HopE band is still
present and BambL-reactive in the Δ946 mutant during Western blotting. Furthermore,
this work also eliminates the possibility that the O-antigen ligase may play the role of
OST for HopE as the same HopE band is BambL-reactive in the ΔwaaL mutant. We
showed that HopE is glycosylated with a fucose-containing glycan, which does not
eliminate non-Lewis Y antigens (such as Lewis X, a, or b) which were presumed to be
exclusively associated with the LPS. Thus, it is still possible that glycosylation in HP is
linked to the LPS synthesis pathway. Further studies are needed to determine the precise
relationship between the two processes, whereby the impetus lies in identifying the OST
for this glycosylation of HopE.
Moreover, the deletion of HP0946 expression also causes the increased generation
of LPS/protein bands reactive to both Lewis Y and BambL. As an inner membrane
protein, the elimination of HP0946 would likely also affect the LPS synthesis pathway as
most enzymes related to this pathway also exist in the inner membrane.
To ensure that lack of BambL-reactive glycoprotein in the ΔhopE mutants and the
antibiotic susceptibility in the Δ946 mutant are true phenotypes, a future direction would
be to facilitate the successful complementation of both mutants. The complementation of
HopE was initiated in this thesis with two suicide plasmids, one containing the HopE
with a His tag and the other without it. However, clones from both transformations
showed no expression of HopE when subjected to an anti-HopE blot. A future direction
for this method would be to use primers that span entirely outside the recombination area
and within the chromosomal DNA, such as 706Tag11 and 706Tag12. Sequencing the
resulting PCR product could indicate if the genes upstream and downstream of the
recombination junction were affected in some way, providing a reason for the loss of
HopE production. Additionally, another attempt can be conducted on transforming VJ
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WT using a suicide plasmid without the DNA sequence for the His tag at all. The results
of this attempt would determine if the His tag DNA sequence was the reason for the loss
of the protein expression or if the act of recombination resulted in an unforeseen mutation
elsewhere in the chromosome that affected HopE production.
By successfully creating a plasmid that will subsequently be transformed into the
recipient strain ΔhopE and express HopE, this would be the crucial step in working
towards complementation of HopE. Once this step is completed and the correct antibiotic
cassettes are being utilized, the VJ ΔhopE mutant can be complemented and the
glycosylation of HopE can be confirmed. Similarly, a plasmid vector containing the full
HP0946 gene construct should also be created and transformed into the Δ946 recipient
strain for verification of the LPS variation and antibiotic susceptibility phenotypes.
Currently, the functional impact of neither HopE nor its putative glycosylation has
been elucidated, as objective 3 had suggested. Antibiotic testing with three different
substances of varying characteristics (levofloxacin, amoxicillin and clarithromycin) all
present the same results, demonstrating that HopE does not play a discernible role in
antibiotic susceptibility. However, a novel discovery indicates that HP0946 may have a
link to antibiotic sensitivity since eliminating HP0946 causes an increase in
clarithromycin susceptibility for the Δ946 and ΔhopE/Δ946 mutants. One explanation put
forth for this involved HP0946 facilitating the prevention of entry of antibiotics across
the inner membrane or extruding the antibiotic back to the periplasm. Therefore, the
future direction for this aspect of the project would be to complement the Δ946 mutant
and test with the same antibiotics to ensure this phenotype is a result of the loss of
HP0946. Once this is established, a further examination into the mechanism of HP0946
in relation to antibiotics must follow.
In summary, we showed that HopE is glycosylated with a fucose-containing
glycan, and it may have a link to LPS synthesis which will be corroborated once the
complementation has been completed. HP0946 was observed to not be the OST of
interest, and neither was WaaL. We also show that HP0946’s elimination appears to
result in a generation of more LPS or glycoproteins that are BambL and Lewis Y
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reactive. HP0946 also may be linked to antibiotic interaction and may increase
susceptibility to clarithromycin when its protein expression is lost. These discoveries
provide new insight into the mechanisms of H. pylori and the tools it uses to evade the
host immune response and develop immunity to current antibiotic treatments.
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